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A B S T R A C T
Background
Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised
countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that inhibit
vascular endothelial growth factor, an angiogenic cytokine that promotes vascular leakage and growth, thereby preventing its pathological
angiogenesis. Ranibizumab is approved for intravitreal use to treat neovascular AMD, while bevacizumab is approved for intravenous use
as a cancer therapy. However, due to the biological similarity of the two drugs, bevacizumab is widely used off-label to treat neovascular
AMD.
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Objectives
To assess the systemic safety of intravitreal bevacizumab (brand name Avastin®; Genentech/Roche) compared with intravitreal
ranibizumab (brand name Lucentis®; Novartis/Genentech) in people with neovascular AMD. Primary outcomes were death and
All serious systemic adverse events (All SSAEs), the latter as a composite outcome in accordance with the International Conference
on Harmonisation Good Clinical Practice. Secondary outcomes examined specific SSAEs: fatal and non-fatal myocardial infarctions,
strokes, arteriothrombotic events, serious infections, and events grouped in some Medical Dictionary for Regulatory Activities System
Organ Classes (MedDRA SOC). We assessed the safety at the longest available follow-up to a maximum of two years.
Search methods
We searched CENTRAL, MEDLINE, EMBASE and other online databases up to 27 March 2014. We also searched abstracts and
clinical study presentations at meetings, trial registries, and contacted authors of included studies when we had questions.
Selection criteria
Randomised controlled trials (RCTs) directly comparing intravitreal bevacizumab (1.25 mg) and ranibizumab (0.5 mg) in people with
neovascular AMD, regardless of publication status, drug dose, treatment regimen, or follow-up length, and whether the SSAEs of
interest were reported in the trial report.
Data collection and analysis
Two authors independently selected studies and assessed the risk of bias for each study. Three authors independently extracted data.
We conducted random-effects meta-analyses for the primary and secondary outcomes. We planned a pre-specified analysis to explore
deaths and All SSAEs at the one-year follow-up.
Main results
We included data from nine studies (3665 participants), including six published (2745 participants) and three unpublished (920
participants) RCTs, none supported by industry. Three studies excluded participants at high cardiovascular risk, increasing clinical
heterogeneity among studies. The studies were well designed, and we did not downgrade the quality of the evidence for any of the
outcomes due to risk of bias. Although the estimated effects of bevacizumab and ranibizumab on our outcomes were similar, we
downgraded the quality of the evidence due to imprecision.
At the maximum follow-up (one or two years), the estimated risk ratio (RR) of death with bevacizumab compared with ranibizumab
was 1.10 (95% confidence interval (CI) 0.78 to 1.57, P value = 0.59; eight studies, 3338 participants; moderate quality evidence).
Based on the event rates in the studies, this gives a risk of death with ranibizumab of 3.4% and with bevacizumab of 3.7% (95% CI
2.7% to 5.3%).
For All SSAEs, the estimated RR was 1.08 (95% CI 0.90 to 1.31, P value = 0.41; nine studies, 3665 participants; low quality evidence).
Based on the event rates in the studies, this gives a risk of SSAEs of 22.2% with ranibizumab and with bevacizumab of 24% (95% CI
20% to 29.1%).
For the secondary outcomes, we could not detect any difference between bevacizumab and ranibizumab, with the exception of
gastrointestinal disorders MedDRA SOC where there was a higher risk with bevacizumab (RR 1.82; 95% CI 1.04 to 3.19, P value =
0.04; six studies, 3190 participants).
Pre-specified analyses of deaths and All SSAEs at one-year follow-up did not substantially alter the findings of our review.
Fixed-effect analysis for deaths did not substantially alter the findings of our review, but fixed-effect analysis of All SSAEs showed an
increased risk for bevacizumab (RR 1.12; 95% CI 1.00 to 1.26, P value = 0.04; nine studies, 3665 participants): the meta-analysis was
dominated by a single study (weight = 46.9%).
The available evidence was sensitive to the exclusion of CATT or unpublished results. For All SSAEs, the exclusion of CATT moved
the overall estimate towards no difference (RR 1.01; 95% CI 0.82 to 1.25, P value = 0.92), while the exclusion of LUCAS yielded a
larger RR, with more SSAEs in the bevacizumab group, largely driven by CATT (RR 1.19; 95% CI 1.06 to 1.34, P value = 0.004).
The exclusion of all unpublished studies produced a RR of 1.12 for death (95% CI 0.78 to 1.62, P value = 0.53) and a RR of 1.21 for
SSAEs (95% CI 1.06 to 1.37, P value = 0.004), indicating a higher risk of SSAEs in those assigned to bevacizumab than ranibizumab.
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Authors’ conclusions
This systematic review of non-industry sponsored RCTs could not determine a difference between intravitreal bevacizumab and
ranibizumab for deaths, All SSAEs, or specific subsets of SSAEs in the first two years of treatment, with the exception of gastrointestinal
disorders. The current evidence is imprecise and might vary across levels of patient risks, but overall suggests that if a difference exists, it
is likely to be small. Health policies for the utilisation of ranibizumab instead of bevacizumab as a routine intervention for neovascular
AMD for reasons of systemic safety are not sustained by evidence. The main results and quality of evidence should be verified once all
trials are fully published.
P L A I N L A N G U A G E S U M M A R Y
Systemic (whole body) safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Background
Neovascular age-related macular degeneration (AMD) is a progressive and chronic disease of the eye, and a leading cause of severe
blindness in elderly populations. The disease is characterised by the abnormal growth of arteries and veins (neovascularisation) in the
macula, a region of the retina (back portion of eye) responsible for central vision. Without treatment, the leakage of these blood vessels
causes swelling and damage to the macula, resulting in a fibrous scar that impairs eyesight. Approximately one out of 10 people with
neovascular AMD suffer legal blindness, accounting for 90% of all cases of severe vision loss due to AMD.
Therapies against neovascular AMD target new blood vessels. Bevacizumab (commercial name Avastin®) and ranibizumab (Lucentis®)
are biological drugs that bind to and block the function of vascular endothelial growth factor (VEGF), a protein released by cells in
the body that stimulates the growth and leakage of blood vessels. The two drugs, accordingly, inhibit the process of neovascularisation.
Ranibizumab is approved to treat neovascular AMD by injection into the eye (intravitreal injection), while bevacizumab is approved as
a cancer therapy by injection into the vein through the skin. The two drugs have similar chemical structures and the same mechanism
of action. Although their benefits are equivalent, it has been hypothesised that the two drugs have different systemic safety profiles,
such that one drug might cause more adverse events (harms) at the level of whole body compared to the other.
Review question
We evaluated whether the two drugs differed in terms of deaths or serious systemic adverse events (SSAEs) in people with neovascular
AMD. The latter refers to medically related events that result in death, are life-threatening, require hospital admission or prolong
hospital stay, or cause persistent or significant disability.
Study characteristics
We included nine randomised controlled trials (RCTs), none supported by industry, with 3665 participants directly comparing beva-
cizumab with ranibizumab. Six RCTs were completed and published, two RCTs were completed, but unpublished, and one was still
in progress. We were able to include safety information from all trials, accessing both published and unpublished data.
Drugs were administered for up to two years according to continuous or discontinuous treatment. In the first, drugs were regularly
administered, irrespective of the remission or progression of the disease; the latter involved ’as needed’ (pro re nata, PRN) or ’treat-
and-extend’ regimens in which the drug was injected less frequently as long as there was no recurrence of neovascular manifestations.
Follow-up for adverse events occurred at regular intervals up to one or two years, irrespective of continuous or discontinuous treatment.
All studies used the approved dosage of ranibizumab (0.5 mg) according to the ’Summary of Product Characteristics’, and the dosage
of bevacizumab most recommended by ophthalmologists for intravitreal injection (1.25 mg).
Three studies excluded patients at high cardiovascular risk. However, four RCTs considered patients at different cardiovascular risks,
representing a wide spectrum of risks and routine practice in hospital settings.
Key results
Our review found the systemic safety of bevacizumab for neovascular AMDtobe similar to that of ranibizumab, except for gastrointestinal
disorders, which was a part of a secondary analysis.
If 1000 people were treated with ranibizumab for one or two years, 34 would die. If treated instead with bevacizumab, between 27
and 53 of them would die. If 1000 people were treated with ranibizumab, 222 would experience one or more SSAEs. If 1000 people
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were treated instead with bevacizumab, between 200 and 291 would experience such an event. Deaths are likely to be unrelated to the
administration of drugs.
Quality of the evidence
We could not fully assess the quality of three unpublished studies. We rated the overall quality of the evidence as low tomoderate because
we could not be certain that one drug was better than the other one on many of our outcomes. Another limitation of the studies was
the participants who were recruited into them, and the fact that studies may have missed measuring the outcomes of interest in a few
individuals that might have experienced a SSAE. Missing information was equally common in participants treated with bevacizumab
and those treated with ranibizumab.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Bevacizumab compared with ranibizumab for neovascular age-related macular degeneration
Patient or population: patients with neovascular age-related macular degeneration
Intervention: bevacizumab
Comparison: ranibizumab
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Ranibizumab Bevacizumab
All-cause death
Follow-up: 1 to 2 years
34 per 1000 37 per 1000
(27 to 53)
RR 1.10 (0.78 to 1.57) 3338
(8)
⊕⊕⊕©
moderate 1,2,3
All serious systemic ad-
verse events
Follow-up: 1 to 2 years
222 per 1000 240 per 1000
(200 to 291)
RR 1.08 (0.90 to 1.31) 3665
(9)
⊕⊕©©
low 1,2,3,4
Infection 37 per 1000 50 per 1000
(36 to 69)
RR 1.34 (0.97 to 1.86) 3190
(6)
⊕⊕⊕©
moderate 1,2,3
Arterial thromboembolic
event
35 per 1000 32 per 1000
(21 to 47)
RR 0.92 (0.62 to 1.37) 3190
(6)
⊕⊕⊕©
moderate 1,2,3
Myocardial infarction 14 per 1000 12 per 1000
(6 to 23)
RR 0.84 (0.42 to 1.66) 3190
(6)
⊕⊕⊕©
moderate 1,2,3
Stroke 11 per 1000 9 per 1000
(5 to 19)
RR 0.83 (0.42 to 1.66) 3190
(6)
⊕⊕⊕©
moderate 1,2,3
Gastrointestinal disor-
ders MedDRA class
16 per 1000 29 per 1000
(16 to 50)
RR 1.82
(1.04 to 3.19)
3190
(6)
⊕⊕⊕©
moderate 1,4,5
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*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1For all outcomes, we judged the impact of missing data to be unclear: even the low rate of efficacy missing data, which was in the range
of 5% to 10% for most studies, could have impacted on rare adverse events differences. However, we considered that a number of
studies used an active monitoring for almost all participants across both arms, reducing the chance of missing SSAEs. We did not
decrease the overall quality for risk of bias.
2People at high cardiovascular risk were excluded in Biswas 2011, MANTA, and Subramanian 2010. BRAMD, CATT, GEFAL, and IVAN
did not report exclusion criteria based on cardiovascular risks, and we considered them to represent a wide spectrum of risks as well
as routine practice in secondary care settings. However, it is unclear as to how the results can be applied to high-risk patients requiring
long-term treatment. We did not decrease the overall quality for indirectness.
3Wide 95% confidence interval considering relative risk and/or absolute events. We did decrease the overall quality for imprecision (-1).
4The meta-analytic estimate was sensitive to the exclusion of CATT and LUCAS, as well as two unpublished studies. We did decrease
the overall quality for inconsistency (-1).
5’Summary of findings’ table outcome not pre-specified in the review protocol.
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B A C K G R O U N D
Description of the condition
Age-related macular degeneration (AMD) is a progressive and
chronic disease of the retina. According to numerous population-
based studies including individuals aged 30 to 97 years, the pooled
prevalence of AMD at any stage is 8.7% (95% credible interval
(CrI) 4.3% to 17.4%) and the prevalence of late-stage AMD is
0.4% (CrI 0.2% to 0.8%), with higher prevalence observed in Eu-
ropean versus Asian or African populations (e.g., late AMD: 0.5%,
0.3% and 0.4%, respectively) (Wong 2014). Age is the main risk
factor for AMD across ethnic groups: the late stage ranges from
0.1% (95% CrI 0.1% to 0.2%) among individuals aged 50 to 59
years to 3.3% (95% CrI 2.2% to 4.6%) among individuals aged
80 years or more. The global projected cases of AMD in 2040 are
288 million (95% CrI 205 to 399), with the largest number of
cases in Asia and Europe (Wong 2014).
In Western countries, AMD is the leading cause of severe, irre-
versible blindness in individuals over 50 years of age (Chappelow
2008). The loss of visual perception occurs primarily in the late
stages of the disease due to neovascular (i.e., wet) AMD, geo-
graphic atrophy, or a combinationof the twoprocesses (Lim 2012).
In particular, neovascular AMD accounts for 90% of all cases of
severe vision loss due to AMD (Ferris 1984). In neovascular AMD,
blood vessels grow aberrantly into the subretinal, intraretinal, and
intrachoroidal space. These abnormal vessels can leak serous fluid,
including lipid and blood, causing swelling and damage to the
macula (Green 1993). Without treatment, its natural course will
result in a fibrous scar that greatly diminishes central visual ca-
pacity. In the UK, the estimated annual incidence of neovascular
AMD is 2.3 (95% CrI 1.4 to 4.0) per 1000 women and 1.4 (95%
CrI 0.8 to 2.4) per 1000 men (Owen 2012).
Description of the intervention
Vascular endothelial growth factor (VEGF) is an angiogenic cy-
tokine that promotes vascular leakage and growth. Its signalling
is over expressed in neovascular AMD as well as in some tumours
(e.g., colorectal cancer). Accordingly, VEGF inhibitors such as be-
vacizumab and ranibizumab have been used to block its patho-
logical angiogenesis. Bevacizumab is approved by drug regula-
tory authorities for intravenous use as a cancer therapy, whereas
ranibizumab is approved for intravitreal use in the treatment of
neovascular AMD.
Bevacizumab and ranibizumab derive from the same anti-VEGF
mousemonoclonal antibody (Ferrara 2006), but differ in themon-
oclonal antibody fragment and glycosylation of proteins (Meyer
2011). In intravitreal injections, both drugs can enter systemic cir-
culation, although bevacizumab, a full-length antibody, exhibits a
longer half-life (Avery 2014). The shared molecular structure and
pharmacological profile of the two drugs, as well as bevacizumab’s
therapeutic utility (Braithwaite 2014), have led to the widespread
off-label/unlicensed use of bevacizumab to treat neovascular AMD
as a less expensive alternative to ranibizumab (Miller 2013).
The approved dosage of ranibizumab as indicated in the ’Summary
of Product Characteristics’ is 0.5 mg. After intravitreal adminis-
tration, ranibizumab slowly moves into systemic circulation (Xu
2013). The dosage of bevacizumab for intravitreal injection most
commonly used in published studies is 1.25 mg (Horsley 2009),
as it is not toxic to the retina (Manzano 2006) and is approxi-
mately 400-fold less than the intravenous dose used in cancer ther-
apy (Schmucker 2010). In fact, when administered intravitreally,
only a small fraction of bevacizumab enters systemic circulation
(Kim 2009; Krohne 2008; Stergiou 2011). Retreatment regimens
include continuous (i.e., monthly injections) and discontinuous
treatment, including ’as needed’ (pro re nata (PRN)) and ’treat-
and-extend’ regimens in which the drug is injected less frequently
as long as there is no recurrence of neovascular manifestations.
Why it is important to do this review
The use of bevacizumab or ranibizumab relies on evidence of su-
periority of one drug over the other. A number of factors will in-
fluence the decision, including different profiles for effectiveness,
ocular and systemic adverse events, resource use, and the feasibility
of the intervention in practice. There is evidence that bevacizumab
is associated with a relative improvement in best corrected visual
acuity (BCVA) similar to that of ranibizumab (-1.15 letters; 95%
confidence interval (CI) -2.82 to 0.51). BCVAoutcome favoured a
continuous treatment regimen when compared with a discontinu-
ous regimen (-2.23 letters; 95% CI -3.93 to -0.53) (Chakravarthy
2013).
There is limited evidence that bevacizumab might be associated
with higher ocular adverse events (risk ratio (RR) 3.1; 95% CI 1.1
to 8.9); however, the absolute rates of serious ocular adverse events
(e.g., endophthalmitis, uveitis) were low (≤ 2.1%) (Schmucker
2012), andmay not have related to the drugs, but to the procedure
(i.e., intravitreal injection). Most discordant judgements between
the two drugs focused on differences in their systemic safety.
VEGF has important growth-promoting and maintenance roles
in a variety of cells and tissues, raising concern that these agents
may interfere with normal physiology and worsen conditions such
as coronary or peripheral arterial diseases. VEGF inhibition in
cancer patients treated systemically with bevacizumab, at higher
dosages than are given in neovascular AMD, was found to increase
the risk of fatal events due to haemorrhage (RR 2.77; 95% CI
1.07 to 7.16), neutropenia (RR 2.37; 95% CI 0.61 to 9.18), and
gastrointestinal perforation (RR 2.45; 95% CI 0.63 to 9.51) (
Ranpura 2011). Accordingly, concerns have been expressed about
the systemic safety of anti-VEGF drugs, even at the small doses
delivered with intravitreal injection (Lim 2011).
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Comparison of AMD Treatments Trials (CATT), the first
published large randomised controlled trial (RCT) comparing
ranibizumab directly with bevacizumab, reported a statistically sig-
nificant finding of an excess of serious systemic adverse events (e.g.,
life-threatening or resulting in significant patient disability) re-
lated to bevacizumabwhen comparedwith ranibizumab (RR1.29;
95% CI 1.01 to 1.66). The publication of results from a second
large RCT, Inhibition of VEGF in Age-related Choroidal Neovas-
cularisation (IVAN) (Chakravarthy 2013), and the concomitant
meta-analysis of the CATT and IVAN safety results at two years
prompted by the IVAN and CATT data monitoring committees,
again showed that the sum of all serious adverse events differed
by treatment regimen. However, when serious adverse events were
compared by organ system class or by specific adverse events (e.g.,
arterial thrombotic event), there were no differences between the
drugs. These results and their varying interpretations fuelledmed-
ical and health policy debates on the off-label use of bevacizumab
as a far less costly alternative to ranibizumab.
O B J E C T I V E S
To assess the systemic safety of intravitreal bevacizumab (brand
name Avastin®; Genentech/Roche) compared with intravitreal
ranibizumab (brand name Lucentis®; Novartis/Genentech) in
people with neovascular AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included head-to-head randomised controlled trials (RCTs)
comparing bevacizumab and ranibizumab in people affected by
neovascular age-related macular degeneration (AMD). We in-
cluded trials irrespective of the dosage, whether treatment is con-
tinuous or discontinuous, or duration of follow-up.
Types of participants
We included people affected by neovascular AMD irrespective of
age, sex, or progression of the condition.
Types of interventions
We compared the systemic safety of intravitreal bevacizumab
(brand name Avastin®; Genentech/Roche) with ranibizumab
(brand name Lucentis®; Novartis/Genentech). For this review,
we did not consider placebo-controlled trials and trials compar-
ing other anti-vascular endothelial growth factor (VEGF) agents
approved for neovascular AMD (e.g., pegaptanib and aflibercept).
These studies can contribute to a large network meta-analysis that
simultaneously summarises direct evidence (which comes from
studies directly randomising treatments of interest) and indirect
evidence (which comes from studies comparing treatments of in-
terest with placebo) (Salanti 2008). We will be completing the
network meta-analysis as a second phase of this project, to address
the issue of the relative effectiveness and safety across a network
of RCTs testing anti-VEGF agents.
Types of outcome measures
Primary outcomes
Primary outcome domains included:
1. All-cause deaths.
2. All serious systemic adverse events (hereinafter referred to as
All SSAEs), the sum of individuals affected by one or more
SSAEs recorded in a trial. The International Conference on
Harmonisation Good Clinical Practice (ICH GCP) Guideline
defines SSAEs as medical occurrences that result in death, are
life-threatening, require hospital admission or prolongation of
hospital stay, cause persistent or significant disability/incapacity,
or are medically important events or reactions (ICH 2014). We
accepted the definition of SSAE adopted by the study authors,
while recognising that some studies may not have adopted the
ICH GCP Guideline.
Secondary outcomes
Secondary outcome domains included:
1. Myocardial infarction (MI).
2. Stroke.
3. Arteriothrombotic event, defined as any participant who
has experienced at least one of the following events: a)
myocardial infarction, b) non-haemorrhaging stroke, c) angina,
d) ischaemic heart disease, e) thrombosis, or f ) death from
cardiovascular diseases.
4. Serious haemorrhage as defined by each study, including,
but not limited to, cerebral, pulmonary, and gastrointestinal
haemorrhage (these are usually defined as a haemorrhage that is
associated with anaemia, transfusion, haemostatic intervention,
hospitalisation, or fatal bleeding).
5. Serious neutropenia as defined by each study (these are
usually defined as neutropenia of grade 3 and 4 associated with
sepsis and life-threatening infections) (National Cancer Institute
2003).
6. Gastrointestinal perforation.
7. Serious infection as defined by each study, including, but
not limited to, pneumonia, lung abscess, and pyothorax (these
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are usually defined as an infection associated with the use of
intravenous antibiotic, hospitalisation, intubation, or death). We
excluded ocular infections.
8. Treatment-related drug discontinuation.
9. SSAEs classified according to the Medical Dictionary for
Regulatory Activities System Organ Classes (MedDRA SOC)
(version 17.0) (ICH 2014), including: benign, malignant, or
unspecified neoplasms; cardiovascular disorders; gastrointestinal
disorders; general disorders and administration site conditions;
infections and infestations; nervous system disorders; and
respiratory, thoracic, and mediastinal disorders.
10. Serious adverse events previously associated with drugs
affecting the VEGF pathway (i.e., arteriothrombotic events,
systemic haemorrhage, congestive heart failure, venous
thrombotic events, hypertension, and vascular death).
The SSAEs classified byMedDRA SOCdiffered fromour primary
outcome All SSAEs as they explored specific subsets of SSAEs,
providing the opportunity to explore the biological plausibility of
each.
Search methods for identification of studies
Electronic searches
We systematically searched CENTRAL (which contains the
Cochrane Eyes and Vision Group Trials Register) (2014, Issue 1),
Ovid MEDLINE, (January 1946 to March 2014) and EMBASE
(January 1980 to March 2014). We used and updated the search
strategy prepared for an update of a Cochrane Review on antian-
giogenic drug effectiveness for neovascular AMD(Solomon 2014).
RCTs that investigated an anti-VEGF treatment compared to an-
other treatment, sham treatment, or no treatment were eligible.
We also searched clinical trial registers, including the metaRegister
of Controlled Trials (mRCT) (www.controlled-trials.com), Clini-
calTrials.gov (www.clinicaltrials.gov) and theWorld Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en) to identify other ongo-
ing studies or completed studies that have not yet been published.
We did not use any date or language restrictions in the electronic
searches for trials. We last searched the electronic databases on
27 March 2014. For unpublished RCTs, we searched the Internet
for pre-publication study presentations at conferences or meetings
and contacted study authors seeking information on safety data.
Searching other resources
We searched the reference lists of relevant studies to identify ad-
ditional studies.
Data collection and analysis
We collected and combined outcomes at the maximum follow-up
times reported up to a maximum of two years, since this corre-
sponds to the maximal cumulative drug dosage. We conducted a
pre-specified subgroup analysis to explore SSAE outcome at the
one-year follow-up.
Selection of studies
Two investigators (EL and GV) independently screened the titles
and abstracts of studies identified through the literature searches
and additional sources. We retrieved and independently assessed
the full text or unpublished reports using predefined inclusion
criteria. We resolved discrepancies through discussion and, when
necessary, by consulting an additional investigator (LM).
Data extraction and management
Two investigators independently extracted data (EL and GV) on
study characteristics and entered data into RevMan (RevMan
2014). Three investigators extracted data on our safety primary
and secondary outcomes (EL, GV, and KK).
Assessment of risk of bias in included studies
We assessed the risk of bias in each included study following the
criteria outlined in Chapter 8 of theCochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011), which addresses
the following key domains: randomisation sequence generation;
allocation concealment; masking (blinding) of participants, trial
personnel, and outcome assessors; incomplete outcome data; se-
lective outcome reporting (i.e., absence of data or non-publica-
tion of deaths and All SSAEs - our primary outcomes); and other
sources of bias (e.g., early termination of a trial due to benefits
or the failure of authors to disclose the study’s source of financial
support).
We evaluated additional risk of bias items specific to adverse events
using the following items: (1) adverse event definition: if the def-
inition of adverse events was pre-specified in the protocol and
collected based on standard criteria or classification system (e.g.,
MedDRA SOC) and (2) method of adverse event assessment: if
the researchers actively monitored for adverse events or simply
provided spontaneous reporting of adverse events that arose dur-
ing the study.
If the information in published study reports or unpublished sup-
porting documents (e.g., meeting abstracts or presentations) was
partial or inadequate to assess the risk of bias, we contacted the
study authors for clarification. If the authors did not respond, we
assessed the risk of bias based on the available information.
Measures of treatment effect
9Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We used the risk ratio (RR) to estimate the relative safety effect of
the two anti-VEGF drugs.
Unit of analysis issues
Individual participants served as the unit of analysis. Since re-
peated SSAEs can occur in the same participant, we considered
the number of individuals with at least one SSAE, rather than the
number of SSAEs. However, the individual-level analysis might
decrease the statistical power of meta-analyses.
Dealing with missing data
In all studies, we carried out the analyses, as far as possible, on an
intention-to-treat basis. In other words, we attempted to include
all participants randomised to each group in the analyses, irrespec-
tive of the treatment received or if the participants completed the
study follow-up (Akl 2013). As a second option, we collected data
on participants who received at least one dose of study medication:
as treated analysis.
If there was a discrepancy between the number randomised and
the number analysed in each treatment group, we calculated and
reported the percentage lost to follow-up in each group. Where
data were inadequate to assess the extent of SSAEs, we contacted
the principal investigators of included studies to provide any un-
reported data. Where it was not possible to obtain information
on missing data, we recorded this in the data collection form and
reported it in the ’Risk of bias’ table. We further discussed the ex-
tent to which the missing data could alter the results/conclusions
of the review.
Assessment of heterogeneity
We anticipated that a low number of RCTs in a pairwise compari-
son (due to either the paucity of studies in the field or incomplete
reporting) would prevent the formal assessment of statistical het-
erogeneity. Nevertheless, we calculated the Chi2 and I2 statistics.
For the latter, we also calculated and reported the 95% CI for
primary outcomes. I2 estimates the variability among individual
study relative risk estimates that is due to statistical heterogeneity
rather than to sampling error (Higgins 2003).
Assessment of reporting biases
We anticipated that a low number of RCTs in a pairwise compari-
son would also prevent the formal assessment of publication bias.
Data synthesis
In this context, we reasoned that there may be true differences
across the population of potential studies as theymay have enrolled
participants at different risk levels for adverse events. For instance,
some studies might have included participants at high risk for
arteriothrombotic events, while others may have excluded such
participants. For this reason, we used a Mantel-Haenszel random-
effects model for meta-analyses, which provides a robust estimate
when pooling sparse data (Robins 1986). We did not formally
adjust for multiplicity of comparisons, but considered this issue
when interpreting the analyses.
’Summary of findings’ table
We summarised the strength of evidence for all-cause deaths,
All SSAEs, serious systemic infections, arterial thromboembolic
events, myocardial infarctions, and strokes, using the Grading
of Recommendations Assessment, Development, and Evaluation
(GRADE)methodology (Guyatt 2008).We used an iterative elec-
tronic correspondence discussion process to reach consensus on: a)
the factors that affect confidence in the estimate of effects, includ-
ing risk of bias (i.e., design and study limitations), imprecision,
indirectness (directness in the GRADE approach includes gen-
eralisability and applicability), inconsistency of results (i.e., het-
erogeneity), magnitude of effect, and issues of residual plausible
confounding and b) the rating of the evidence. We expected the
imprecision of RRs to be a limitation when investigating deaths
and adverse events in RCTs, which might be rare, therefore we
followed the GRADE guidelines for assessing this quality item
(Guyatt 2011a;Guyatt 2011b).We focused on the 95%CI around
the absolute effects, considering a follow-up between one and two
years as sufficient. We adopted an absolute minimal difference of
1% for deaths and 5% for All SSAEs as clinically relevant. When
the 95%CI included treatment effects above these thresholds and,
therefore, did not exclude an absolute detrimental effect apprecia-
bly less than 1% and 5%, we evaluated the precision as insufficient
and downgraded the quality of the overall evidence. We adopted
these thresholds based on rating imprecision guidelines (Guyatt
2011b), as well as our own judgement. We settled a clinical deci-
sion threshold boundary of 1% absolute difference as we reasoned
this difference to be important to both patients and health systems.
For example, when the absolute difference in death rates between
ranibizumab and bevacizumab was very small (absolute difference
of 0.3% with a 95% CI ranging from -0.1% to 0.7%), the results
of the meta-analysis excluded an important difference favouring
either drug, and we did not downgrade the quality of evidence for
deaths. We adopted two different imprecision thresholds, 1% or
5%, because the differing importance of the outcome deaths or
serious adverse events influenced our judgement.
We presented the overall evidence in a ’Summary of findings’ table
with summary estimates of absolute and relative effects and their
quality according to the GRADE methodology (Guyatt 2013).
For each outcome, we categorised our confidence in the estimate
of effect as one of four levels, ranging from very low to high.
Subgroup analysis and investigation of heterogeneity
We did not plan a subgroup analysis for this review.
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Sensitivity analysis
We computed aMantel-Haenszel RR using a fixed-effect model to
investigate any influence of small study effects on the pooled RR,
since the random-effects model tends to attribute greater weight
to small studies with increasing heterogeneity (Sterne 2011).
We performed a sensitivity analysis, excluding unpublished data,
as well as a leave-one-out meta-analysis to assess the independent
influence of each study on the summary estimate (Tobias 1999).
R E S U L T S
Description of studies
Results of the search
Figure 1 illustrates the process by which studies were selected for
inclusion in our meta-analysis.
Figure 1. Study flow diagram for screened, included, and excluded study reports
Included studies
Refer to Characteristics of included studies. Nine RCTs (3665
participants) met our eligibility criteria. Of these, six RCTs
were completed and published (Biswas 2011; CATT; GEFAL;
IVAN; MANTA; Subramanian 2010), comprising a total of
1362 participants treated with bevacizumab and 1383 treated
with ranibizumab. CATT and IVAN provided data at two years
(Chakravarthy 2013; Martin 2012), which we used for the pri-
mary analyses, whereas the remaining four studies provided data at
a maximum follow-up of one year. Three RCTs were unpublished:
two were completed (BRAMD; LUCAS), and one is still ongoing
(VIBERA). Unpublished data comprised a total of 482 partici-
pants treatedwith bevacizumab and438 treatedwith ranibizumab.
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We extracted the unpublished data of LUCAS from a presentation
given by the principal investigator at the American Academy of
Ophthalmology Retina Subspecialty meeting in 2014. Although
this presentation provided information on death and individual
cardiovascular SSAE, it did not report the total number of All
SSAEs as defined by the study authors. Accordingly, we derived
the total number of All SSAEs from the sum of all mutually ex-
clusive SSAEs.We contacted the principal investigator of LUCAS
and requested data on this outcome; however, the investigator de-
clined to provide additional information until the trial’s publica-
tion. We extracted the unpublished data of BRAMD from a pre-
sentation at the 2014 meeting of the Association for Research in
Vision and Ophthalmology. We contacted the principal investi-
gator of BRAMD to obtain additional data, but did not receive
a response. Unpublished data of VIBERA were provided by the
study authors. Two studies were conducted in the USA (CATT;
Subramanian 2010), six in Europe (BRAMD; GEFAL; IVAN;
LUCAS; MANTA; VIBERA), and one in India (Biswas 2011).
Studies included populations at variable baseline cardiovascular
risks. The proportion of CATT participants who had a prior his-
tory of MI, stroke, and transient ischaemic attack at baseline were
12%, 6%, and 6% of the cases, respectively. These figures were
lower in GEFAL (4%, 4%, and < 0.5%) and IVAN (7.5%, 2.3%,
and 5%), while Biswas 2011, MANTA, and Subramanian 2010
excluded participants with a previous history of vascular throm-
boembolic events. All trials were non-industry sponsored.
Excluded studies
We did not exclude any head-to-head RCTs in this review.
Risk of bias in included studies
The risk of bias for each study is presented in Figure 2. Twounpub-
lished studies were at unclear risk of bias for all items (BRAMD;
LUCAS), since limited information was available and the trial au-
thors declined our request for additional information. It is impor-
tant to note that our ’Risk of bias’ assessment differed from that
conducted in the parallel efficacy review (Solomon 2014, update
under peer review) due to the two reviews’ differing outcomes of
interest, access to additional information (i.e., from trial authors),
and use of additional ’Risk of bias’ dimensions related to adverse
events.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The remaining studies generally reported details about random
sequence generation and allocation concealment. The treatment
allocation was described as masked to clinicians and participants
in seven studies (Biswas 2011; CATT; GEFAL; IVAN; MANTA;
Subramanian 2010; VIBERA).
Blinding
In CATT, about half of the participants treated with ranibizumab
and a quarter of those treated with bevacizumab may have been
aware of their drug assignment through billing reports, while a neg-
ligible fraction of participants were unmasked in IVAN. VIBERA
used double-masking. In GEFAL and Subramanian 2010, inves-
tigators did not report any issue with masking, while we could not
find information about the other trials.
Incomplete outcome data
We contacted study authors for additional information about the
risk of bias concerning the missing outcome data: this seemed to
be a potential problem across studies since even low rates of miss-
ing data, which were between 5% and 10% at the end of follow-
up in all studies, could impact estimates for the relative risk of
SSAEs. Nevertheless, the opportunity to miss SSAEs during the
maintenance period was unlikely to have occurred since all studies,
except Biswas 2011, had active SSAE monitoring between injec-
tions. Furthermore, missing data were equally distributed between
arms, except CATT, in which more information was missing from
the bevacizumab arm (35 versus 21 missing data).
Selective reporting
All studies measured our primary outcomes. Although BRAMD,
LUCAS, and VIBERA have not yet been published, we were able
to collect data about deaths and All SSAEs.
Other potential sources of bias
One trial was closed prematurely due to poor recruitment
(Subramanian 2010), a common reason for the discontinuation of
RCTs (Kasenda 2014). Although empirical evidence demonstrates
that discontinued RCTs, on average, overestimate treatment ef-
fects, biases are usually associated with RCTs that have been pre-
maturely discontinued for superiority (Bassler 2013). Accordingly,
we decided to rate this study at unclear risk of bias.
Risk of bias related to adverse events
Published studies (CATT;GEFAL; IVAN) andVIBERA appeared
to have implemented an appropriate, pre-specified definition of
SSAEs and activelymonitored them, except for Subramanian 2010
that did not use a pre-specified definition of SSAEs, but actively
monitored participants for signs and symptoms possibly related
to adverse events, and Biswas 2011 and MANTA, for which both
the definition and monitoring of SSAEs were unclear.
Effects of interventions
See: Summary of findings for the main comparison
Adverse events with bevacizumab compared with
ranibizumab
Figure 3 shows the summary risk ratio (RR) for deaths from eight
studies, comprising 3338 participants. The RR of all-cause death
for bevacizumab compared with ranibizumab is 1.10 (95% confi-
dence interval (CI) 0.78 to 1.57, P value = 0.58). Between-study
statistical heterogeneity was low (I2 = 0%; 95% CI 0% to 71%;
Analysis 1.1).
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Figure 3. Forest plot of comparison: 1 Bevacizumab versus ranibizumab, primary analysis at longest follow-
up, outcome: 1.1 All-cause death.
Figure 4 shows the summary RR for All SSAEs (serious systemic
adverse events) from nine studies, comprising 3665 participants.
The RR of All SSAEs in bevacizumab compared with ranibizumab
is 1.08 (95% CI 0.90 to 1.31, P value = 0.42) (Analysis 1.2).
Heterogeneity was moderate (I2 = 41%; 95% CI 0% to 74%).
Figure 4. Forest plot of comparison: 1 Bevacizumab versus ranibizumab, longest follow-up, outcome: 1.2 All
serious systemic adverse events.
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None of the studies reported serious gastrointestinal perforation,
neutropenia, and treatment-related drug discontinuations. We ex-
tracted six secondary outcomes from six studies: arterial throm-
boembolic events, infections, myocardial infarctions, non-ocu-
lar haemorrhages, strokes, and vascular events associated with
anti-VEGF treatment. We did not find any statistically signifi-
cant difference in secondary outcomes between bevacizumab and
ranibizumab (Analysis 1.3; Analysis 1.4; Analysis 1.5; Analysis 1.6;
Analysis 1.7; Analysis 1.8; Analysis 1.9; Analysis 1.10; Analysis
1.11; Analysis 1.12; Analysis 1.14: Analysis 1.15; Analysis 1.16;
Analysis 1.17): all comparisons gave estimates with wide CIs with
the exception of gastrointestinal disorders MedDRA SOC (RR
1.82; 95% CI 1.04 to 3.19) (Analysis 1.13).
The main results should be verified once BRAMD, LUCAS, and
VIBERA are fully published.
Sensitivity and subgroup analyses
The one-year random-effects estimates for the relative risk of death
(RR 1.23; 95% CI 0.72 to 2.10, P value = 0.45) (Analysis 2.1)
and the relative risk of All SSAEs (RR 1.11; 95% CI 0.90 to
1.37, P value = 0.33) (Analysis 2.2) in participants assigned to
bevacizumab versus ranibizumab were consistent with estimates
derived at the end of the longer follow-up.
Influence (leave-one-out) analyses did not show any influential
studies on the RR for death. For All SSAEs, the influence analysis
showed that our results were influenced by CATT and LUCAS.
The exclusion of CATTmoved the overall estimate towards no dif-
ference (RR 1.01; 95% CI 0.82 to 1.25, P value = 0.92) (Analysis
3.1). The exclusion of LUCAS from the analysis of All SSAEs re-
sulted in a larger RR, with more SSAEs in the bevacizumab group,
largely driven by CATT (RR 1.19; 95% CI 1.06 to 1.34, P value
= 0.004) (Analysis 4.1). The exclusion of all unpublished stud-
ies (BRAMD; LUCAS; VIBERA) yielded a RR of 1.12 for death
(95% CI 0.78 to 1.62, P value = 0.53) (Analysis 5.1) and a RR of
1.21 for SSAEs (95% CI 1.06 to 1.37, P value = 0.004) (Analysis
5.2), indicating a higher risk of SSAEs in those assigned to beva-
cizumab than ranibizumab. For BRAMD and LUCAS, we were
unable to obtain the full definitions of SSAEs and their methods
of assessment (see ’Risk of bias’ assessment).
Using a fixed-effect meta-analysis model for primary and sec-
ondary outcomes on the same studies (Analysis 6.1; Analysis 6.3;
Analysis 6.4; Analysis 6.5; Analysis 6.6; Analysis 6.7; Analysis 6.8;
Analysis 6.9; Analysis 6.10; Analysis 6.11; Analysis 6.12; Analysis
6.14; Analysis 6.15; Analysis 6.16; Analysis 6.17), we did not find
a statistically significant difference between the drugs for deaths.
The fixed-effect meta-analysis estimate of All SSAEs was statisti-
cally significant (RR 1.12; 95% CI 1.00 to 1.26, P value = 0.04)
(Analysis 6.2). Themeta-analysis was dominated by a single study,
CATT (weight = 46.9%). Again, the estimate of gastrointestinal
problems was statistically significant and favoured ranibizumab
(RR 1.93; 95% CI 1.20 to 3.11, P value = 0.007) (Analysis 6.13).
Quality of the evidence
Refer to Summary of findings for the main comparison for the
quality of the evidence for each outcome. In addition to the a pri-
ori selected outcomes, we decided also to report the gastrointesti-
nal Medical Dictionary for Regulatory Activities System Organ
Classes (MedDRA SOC), the only statistically significant differ-
ence we found. Based on the event rates in the studies, the abso-
lute difference between the two drugs is 0.3% in death rates with
a 95% CI ranging from -0.8% to 1.9%, and 1.8% in All SSAEs
rates with a 95% CI from -2.2% to 6.9%. The results of this sys-
tematic review do not exclude differences larger than 1% and 5%
for deaths and All SSAEs that could be important to patients. For
gastrointestinal disorders MedDRA SOC, the absolute difference
is 1.3% with more events in the bevacizumab arm and a 95%
CI ranging from 1.3% to 3.4%. Using GRADE, we assessed the
overall quality of the evidence. We began with a GRADE score of
four points as the total evidence derives from nine RCTs. We then
addressed potential reasons to rate down or up the overall quality
of evidence. We downgraded the evidence due to uncertainties in
the absolute risks for all outcomes, subtracting one point from the
total score for imprecision. We subtracted an additional point for
inconsistency as themeta-analysis of All SSAEswas sensitive to the
exclusion of CATT or unpublished studies (BRAMD; LUCAS;
VIBERA) which, together with the moderate I2 value in the main
analysis, we interpreted as evidence of heterogeneity. Thus, the ev-
idence suggests that the true relative safety of bevacizumab versus
ranibizumab could be different from that observed in our overall
estimates.
The quality of evidence should be reassessed once BRAMD,
LUCAS, and VIBERA are fully published.
D I S C U S S I O N
Summary of main results
Our systematic review on the systemic safety of bevacizumab di-
rectly compared with ranibizumab at one to two years of follow-up
in randomised controlled trials (RCTs) on people with neovascular
age-related macular degeneration (AMD) did not find conclusive
or compelling evidence of an increased or decreased risk of deaths
and serious systemic adverse events (SSAEs) - an outcome with
qualifying events of death, life-threatening events, hospitalisation,
and disability. Although one of our primary outcomes was com-
posite, performed to gain statistical power to show any effects on
SSAEs, the 95% confidence interval (CI) around the pooled esti-
mate of risk ratio (RR) included unity, from0.90 to 1.31.With the
exception of gastrointestinal disorders, RR estimates for secondary
outcomes did not indicate statistically significant differences be-
tweenbevacizumab and ranibizumab, although the point estimates
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were imprecise. For instance, a few more events were registered in
the bevacizumab arm for the cardiac disorder Medical Dictionary
for Regulatory Activities System Organ Classes (MedDRA SOC),
while a few more events were registered in the ranibizumab arm
for myocardial infarction or stroke, with negligible differences.
Gastrointestinal disorders were classified according to the Med-
DRA SOC, which includes abdominal pain, colitis, Crohn’s dis-
ease, duodenal ulcer, dyspepsia, faecaloma, intestinal obstruction,
intestinal perforation, pancreatitis, and vomiting. The rate of these
events was low in both groups (1.6% for ranibizumab and 2.9%
for bevacizumab). The components of this outcome have different
clinical importance, with gastrointestinal perforation as one of the
most clinically relevant adverse events. Gastrointestinal perfora-
tion has been recognised with the systemic use of bevacizumab in
patients with cancer (eMC 2014; Hapani 2009), but its incidence
was limited (0.9%; 95% CI 0.7% to 1.2%). It remains unclear
whether low-dose ocular administration might or might not cause
similar harms. We were unable to collect data on the effect of the
drugs on gastrointestinal perforation as well as other outcomes of
interest, such as severe neutropenia, since they were reported in
only one study.
Initial reports of studies exploring the relative safety of beva-
cizumab and ranibizumab indicated a possible increased risk for
bevacizumab (CATT), with subsequent studies showing no in-
creased risk (Biswas 2011; BRAMD; GEFAL; IVAN; LUCAS;
MANTA; Subramanian 2010; VIBERA), therefore the sequence
of findings conforms to what has been called the Proteus phe-
nomenon (Ioannidis 2005a).However, diverging from the Proteus
phenomenon, in which the first trial is small and opportunistic,
in our context the CATT study is a large RCT that is considered a
major breakthrough of independent research. Moreover, it is not
uncommon for there to be conflicting results between a large RCT
and meta-analyses on the same topic (LeLorier 1997). Reasons for
these discrepancies include different patient populations: CATT
may have included patients with diverse baseline risks for SSAEs
compared with other included RCTs. Additionally, a few patients
at high risks may greatly influence the overall estimate (Ioannidis
1997): CATT accounts for the majority of the SSAEs of interest
recorded in ourmeta-analysis, as shown in our leave-one-out sensi-
tivity analysis. There are two possible interpretations of these find-
ings. First, the safety of the two drugs is not the same across differ-
ent levels of patient risk. However, trials that also included patients
at high risks did not replicate CATT findings (BRAMD; CATT;
GEFAL; IVAN). Second, the two drugs have the same safety for
all patients, and the reasons for differences relate to the limitations
of individual trials. The CATT investigators carefully considered
the potential failure of their masking efforts: through billing doc-
uments, patients and health professionals may have known the
intervention assigned. This ancillary information might have led
to disproportionate and varying levels of attention to SSAEs in
patients by health professionals. Our study calls for a more cau-
tious interpretation of the CATT SSAE finding: the result of one
trial is not substantially significant and certain enough to activate
drug policies (i.e., restricted reimbursement for the off-label use
of medicines). Instead, we urge decision-makers to evaluate the
result based on its substantive robustness and replicability, com-
ponents that a community with rational standards for interpreting
evidence would agree are necessary for a result to be considered
relevant and objective, beyond merely statistically significant, to
guide political action (Esarey 2014; Ioannidis 2005b).
Our sensitivity analysis, adopting a fixed-effect, featured a mar-
ginal statistically significant difference (P value = 0.04) favouring
ranibizumab in terms of SSAEs. However, under the assumption
that no between-study heterogeneity existed, the weight of CATT
became more prominent. For the above reasons, we qualitatively
judged the fixed-effect model assumption to be too strong given
the potential differences between the trials in eligibility criteria
(inclusion of high-risk patients or not), baseline disease severity
of patient populations, follow-up duration (one or two years),
and successful masking of participants, investigators, and asses-
sors, with moderate between-study heterogeneity present in the
SSAE analysis (I2 = 41%).
Overall completeness and applicability of
evidence
Health professionals and decision-makers should consider the fol-
lowing factors when interpreting the results of this review:
1. We found nine non-industry sponsored RCTs. This
represents a remarkable amount of investment from researchers
and healthcare systems to answer an important clinical question.
We are unaware of other examples with such a large number of
head-to-head non-industry sponsored RCTs.
2. RCTs were conducted across several countries: Austria,
France, Germany, India, the Netherlands, Norway, UK, and the
USA.
3. The intervention implemented in these RCTs reflects the
doses and regimens that are used in other countries.
4. The included participants represent a wide spectrum of
risks for cardiovascular diseases.
This review provides evidence that is complete, comprehensive,
and applicable to practice.
Quality of the evidence
We graded the overall quality of evidence as moderate for the
majority of outcomes. Most published RCTs were thoroughly
planned and well-executed investigations that reported evidence
on adverse events. Allocation concealment, masking, and attrition
did not raise major concerns.We could not evaluate the quality for
two unpublished studies. Reasons to rate down the overall quality
of evidence included large confidence intervals for all safety out-
comes (i.e., imprecision) and the sensitivity of the SSAE meta-
analysis to a few studies.
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The quality of evidence should be reassessed once the BRAMD
and LUCAS trials are fully published.
Potential biases in the review process
Several important limitations should be noted, mainly due to the
rapid timeline of the review. We obtained limited information
from study authors, and several studies still had items of unclear
risk of bias. The uncertain role of missing data, which is typically
reported only in relation to efficacy, but not for safety, may have
influenced the overall analyses; the direction of the bias is unpre-
dictable, but we believe that the likelihood of this bias is minimal.
The analysis of SSAEs was sensitive to the exclusion of data from
an unpublished study, LUCAS. For this study, we derived SSAEs as
a sum of all single SSAEs listed, assuming that one SSAE occurred
in each participant. We assessed the quality of the evidence based
solely on the adverse event profile related to the two drugs (i.e.,
we did not evaluate the comparative effectiveness of the drugs).
A final limitation is that we did not include: i) outcomes such
as blood pressure or left ventricular ejection fraction, which are
signs that can lead to cardiovascular diseases, or ii) observational
comparative studies (Campbell 2012; Curtis 2010; French 2011),
since this would have required a different review methodology.
Strengths of this review include the extensive search for published
and unpublished studies; a multi-disciplinary team; an in-depth
assessment of key findings in light of single studies as well the over-
all evidence; a standard methodology for conducting the review;
and an a priori definition of the variables to include in the primary
outcome SSAEs.
Agreements and disagreements with other
studies or reviews
Our safety results differed from those of a parallel efficacy re-
view (Solomon 2014, update under peer review), which showed
an increased risk of adverse events for bevacizumab compared to
ranibizumab (RR 1.27; 95% CI 1.06 to 1.52). Our systematic
review included only head-to-head RCTs (the ones that directly
compare bevacizumab and ranibizumab), while Solomon 2014 in-
cluded head-to-head as well standard treatment, placebo, or sham-
controlled RCTs. However, we included three additional RCTs
(BRAMD; LUCAS; VIBERA) compared with the Solomon 2014
update, considering both published and unpublished data. Fur-
thermore, we provide a comprehensive assessment of the contribu-
tion of each RCT to the meta-analyses, a ’Risk of bias’ assessment
that specifically targets risks related to adverse events, and several
analyses to test the robustness of the overall estimates.
Several previous reviews have assessed the safety of antiangiogenic
therapy in people with neovascular AMD. Among these, Cruess
2014 recently reviewed different types of evidence on the safety
of intravitreal bevacizumab in a non-systematic fashion, includ-
ing results from some RCTs and non-randomised studies, stud-
ies on systemic vascular endothelial growth factor (VEGF) lev-
els after intravitreal injections, and differences in molecular struc-
ture of bevacizumab and ranibizumab. However, bevacizumab
was not directly compared with ranibizumab. Chakravarthy 2012
compared serum VEGF levels achieved with bevacizumab and
ranibizumab: these were lower with bevacizumab, although the
change in this biomarker has yet to be associated with adverse out-
comes. Chakravarthy 2013 pooled data from IVAN and CATT at
two years and could not show a difference between bevacizumab
and ranibizumab for deaths and arterial thrombotic events, but
pointed out that SSAEs were higher with bevacizumab because
of the enduring influence of the larger CATT study. In a recent
systematic review and meta-analysis, Thulliez 2014 showed no
differences between bevacizumab and ranibizumab for the risk of
major cardiovascular events or non-ocular haemorrhagic events in
people with neovascular AMD, but found significantly increased
venous thromboembolic events for bevacizumab by cumulating
data from three unspecifiedRCTsdirectly comparing bevacizumab
with ranibizumab, totalling 15 events (12 in the bevacizumab arm
versus three in the ranibizumab arm).We aggregated thromboem-
bolic events with other serious adverse events previously associated
with drugs affecting the VEGF pathway (e.g., arteriothrombotic
events, vascular events, and death), totalling 150 events (79 in
the bevacizumab arm versus 71 in the ranibizumab arm, Analysis
1.11), and did not find significant differences. A systematic review
by Zhang et al analysed both evidence from observational and ex-
perimental studies, comparing bevacizumab with ranibizumab for
efficacy and safety (Zhang 2014). Again, the authors found only
four RCTs (Biswas 2011; CATT; IVAN; Subramanian 2010), in-
terpreted the unadjusted evidence from observational studies as
compelling and free of bias, and overstated the strength of causal
inference in the conclusions. Finally, another systematic review
showed an increased risk of SSAEs in RCTs on several biologics
for any indication (Singh 2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
From the evidence presented in nine randomised controlled trials
(RCTs) comprising 3665 participants with neovascular age-related
macular degeneration (AMD), we did not observe evidence of a
difference in the relative safety between intravitreal bevacizumab
and ranibizumab for deaths, All SSAEs (serious systemic adverse
events), or specific subsets of SSAEs in the first one to two years of
treatment, with the exception of gastrointestinal disordersMedical
Dictionary for Regulatory Activities System Organ Classes (Med-
DRA SOC). With regard to available data on systemic safety, this
review provides no significant evidence to support the preferen-
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tial use of either bevacizumab or ranibizumab in the treatment of
neovascular AMD.
In absolute terms, if 1000 people were treated with ranibizumab
for one or two years, 34 would die and 222 would experience one
or more SSAEs. If 1000 people were treated with bevacizumab
for one or two years, then about 37 would die and 240 would
experience one or more SSAEs. Overall, these differences are small
and consistent with chance variation.
We cannot exclude: i) differences larger than1%and5%for deaths
and All SSAEs that could be important to patients and ii) poten-
tial differences in safety across the levels of patient risk. As elderly
individuals have a variable risk of SSAEs due to multi-morbid-
ity and polypharmacy, the use of bevacizumab and ranibizumab
should be closely monitored by physicians. Health professionals
should recognise the following patient risk factors before expos-
ing patients to bevacizumab: hypertension, left ventricular dys-
function, haemorrhagic events, inherited or acquired coagulopa-
thy, proteinuria, major surgery, and co-treatment with other drugs
that may potentiate the cardiotoxic effects (e.g., anthracyclines)
(Cortes 2012; Saif 2006; Wu 2010). These individual risk factors
should be carefully considered, particularly in patients with mul-
tiple risk factors (e.g., coagulopathy, nephrotic disease, and heart
failure).
Implications for research
The proportion of randomised evidence that has not yet been pub-
lished is limited (about 25%) (BRAMD; LUCAS; VIBERA), but
highly relevant, and deserves timely public dissemination. Trialists
and entities that financially support these trials should consider
and encourage quick dissemination of data, pursuing options such
as fast-track publication (Manzoli 2014).
We do not support the idea of starting new head-to-head RCTs.
Rather, an individual patient data meta-analysis might better as-
sess the exact magnitude of the difference by exploring effect-
modifiers such as drug regimen and susceptible patient subgroups,
such as those at higher cardiovascular risk. The investigators for
the CATT study have made their trial data publicly available and
other trial investigators are urged to do the same. Although RCTs
are the best tool to investigate both the efficacy and safety of in-
terventions, they continue to show limitations related to the poor
reporting of adverse events, as well as their insufficient power to
detect the majority of adverse events, even for common adverse
events. Complementary information on the occurrence of adverse
events may come from observational studies. However, in this set-
ting, observational studies also show limitations. In addition to
the concern about potential biases usually associated with obser-
vational designs, we anticipate that the large difference in terms of
costs between bevacizumab and ranibizumab could affect patient
case-mix, thereby challenging the comparability between groups
(Bosco 2010). For the investigation of safety data, pharmacovigi-
lance remains necessary to explore these issues in the general pop-
ulation, which often comprises of potentially more susceptible pa-
tients.
We believe that our synthesis is a timely and complete summary
of the available evidence from RCTs on the relative safety of beva-
cizumab compared with ranibizumab. We will update the results
of this Cochrane Review once new findings are published.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Biswas 2011
Methods Number randomised (total and per group): 120 participants randomly assigned to
study treatment; 60 in bevacizumab group and 60 in ranibizumab group
Exclusions after randomisation: none
Number analysed (total and per group): 104 total participants; 50 in bevacizumab
group and 54 in ranibizumab group
Unit of analysis: individuals (1 study eye per participant)
Losses to follow-up: 16 participants: reasons for losses to follow-up not reported (10 in
bevacizumab group, 6 in ranibizumab group)
Compliance: 104/120 participants completed the study
Intention-to-treat analysis: no, 16 participants enrolled and randomised were not in-
cluded in analysis
Reported power calculation: “... aimed to enrol a total of 120 patients ... this number
was arrived at by the investigators after considering the sample size of the available
literature”. However, the number of enrolled participants seem not adequate to detect
differences in adverse events
Unusual study design: randomisation logistics were complicated (see ’Risk of bias’ table
below)
Participants Country: 2 study centres in Kolkata, India
Age:not reported for 120 enrolled participants (mean64.4 years in analysed bevacizumab
group; mean 63.5 years in analysed ranibizumab group)
Gender (per cent): not reported for 120 enrolled participants (22/54 (41%) men and
32/54 (59%) women in analysed bevacizumab group; 28/50 (56%) men and 22/50
(44%) woman for analysed ranibizumab group)
Inclusion criteria: age 50 or older; presence of subfoveal or juxta foveal CNV of any
type; active leakage pattern; baseline BCVA between 35 to 70 ETDRS letters; baseline
central macular thickness greater than or equal to 250 µm, measured by OCT
Exclusion criteria: previous treatment for CNV in either eye; macular scarring; any
coexisting ocular disease or pathology; monocular participants; history of ocular surgery
within 6 months of enrolment; history of cerebrovascular accident and myocardial in-
farction
Equivalence of baseline characteristics: gender imbalance between analysed groups
Diagnoses in participants: all with subfoveal or juxta foveal CNV; 24/54 participants
with occult CNV in ranibizumab group and 22/50 participants with occult CNV in
bevacizumab group
History of cardiovascular events at baseline (bevacizumab, ranibizumab): participants
with MI, stroke, TIA were excluded
Interventions Intervention 1: 1.25 mg intravitreal bevacizumab every month for first 3 months; re-
treatment afterwards based on OCT or VA changes
Intervention 2: 0.5 mg intravitreal ranibizumab every month for first 3 months; re-
treatment afterwards based on OCT or VA changes
Length of follow-up:
Planned: 18 months
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Biswas 2011 (Continued)
Actual: 18 months
Outcomes Primary outcomes, as defined: “changes in BCVA and CMT from baseline (month 0)
to month 18”
Secondary outcomes, as reported: blood pressure measurements; reports of unusual
extremity pain
Adverse events: classification method definition not reported
Intervals at which outcome assessed: monthly through 18 months
Notes Type of study: published
Funding sources: reported “nil”
Declarations of interest: “none declared”
Study period: April 2007 to April 2009
Reported subgroup analyses: yes, for participants with predominantly classic CNV
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Using random numbers tables, 60 num-
bers were randomly picked up from 1 to
120 and assigned to group A while the re-
maining sixty numbers were assigned to
group B.”
Allocation concealment (selection bias) Unclear risk “... randomization of the 120 numbers into
two groups was done before initiation of
enrolment itself. Upon initiation of enrol-
ment, the patients were numbered sequen-
tially based on the serial order of enrolment
in the study. Depending on the enrolment
number, the patients were automatically as-
signed to either group A or B based on the
prior randomization of number 1-120 into
two equal groups using randomnumber ta-
bles.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Masking of participants not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All assessors were masked to the group of
patient they were following up.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 16 (13%) participants lost to follow-up
were excluded from the analyses; 6 in the
ranibizumab group and 10 in the beva-
cizumab group
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Biswas 2011 (Continued)
Selective reporting (reporting bias) Unclear risk Reported outcome: adverse events. Deaths
were not mentioned but it is unlikely that
any occurred
Other bias Unclear risk Noprotocol or clinical trial registrationwas
identified for this study. Outcomes were re-
ported for stated outcomes in the methods
section of the published report; however,
only P values were reported for between-
group comparisons and no standard devia-
tion or variance measures were reported for
continuous outcomes
Adverse event definition Unclear risk Not reported
Method of adverse event assessment Unclear risk Not reported
BRAMD
Methods Number randomised (total and per group): total 327 participants
Exclusions after randomisation: not known
Number analysed (total and per group): 161 to 1.25 mg bevacizumab group, 166 to
0.5 mg ranibizumab group
Unit of analysis: individuals (1 study eye per participant)
Losses to follow-up: not available
Compliance: not available
Intention-to-treat analysis: not known
Reported power calculation: not known
Unusual study design: no
Participants Country: USA
Age: not known
Gender (per cent): not known
Inclusion criteria: age 60 or older; primary or recurrent sub-, juxta-, or extrafoveal CNV
secondary to AMD; CNV including retinal angiomatous proliferation, that may benefit
from treatment; BCVA of 78 to 20 letters; size of lesion < 12 disc areas
Exclusion criteria: subretinal haemorrhage involving ≥ 70% of the lesion area; sub-
foveal fibrosis or atrophy in the study eye; CNV of other pathogenesis; history of oc-
ular anti-VEGF treatment within 2 months, triamcinolone within 6 months, or laser
treatment within 1 month; active intraocular inflammation, retinal pigment epithelial
tear involving the macula, or vitreous haemorrhage obscuring view of the posterior pole
in the study eye; IOP > 25 mmHg; cataract extraction within 3 months; myopia > -
8 dioptre; hypersensitivity or allergy to testing agents; mentally or physically unable to
participate; serious disease with probability of death during the study
Equivalence of baseline characteristics: not known
Diagnoses in participants: not known
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BRAMD (Continued)
Interventions Intervention 1: 1.25 mg bevacizumab intravitreal injection monthly for 2 years
Intervention 2: 0.5 mg ranibizumab intravitreal injection monthly for 2 years
Length of follow-up: 12 months
Outcomes Primary outcomes, as defined: primary outcome was the change in BCVA in the study
eye from baseline to 12 months. The non-inferiority margin was set at 4 letters
Secondary outcomes, as defined: proportion of participants losing fewer than 15 letters
at 12 months (responders); proportion of participants with a loss or gain of BCVA less
than 15 letters at 12 months (stabilisers); proportion of participants losing 15 letters
or more of BCVA at 12 months (losers); proportion of participants gaining 15 letters
or more of BCVA at 12 months (gainers); incidence of fluorescein leakage at 4 and 12
months; change in total area of CNV, total area of leakage from CNV, and total lesion
area at 12 months, as determined by the reading centre; absolute and per cent change
in retinal thickness, as measured by OCT at 4 and 12 months; proportion of drop-outs
before the final 12-month assessment; proportion of non-responders at the 4-month
assessment; costs of the 2 treatments
Adverse events: classification method definition not reported
Safety assessments: number of adverse events at 12 months
Intervals at which outcome assessed: 12 months
Notes Full study name: Comparison of Bevacizumab (Avastin) and Ranibizumab (Lucentis)
in Exudative Age-related Macular Degeneration (BRAMD)
Type of study: published as an abstract (ARVO 2014)
Funding sources: sponsors/collaborators: Academic Medical Centre (AMC), Depart-
ment of Ophthalmology; The Netherlands Organization for Health Research and De-
velopment
Declarations of interest: not known
Study period:March 2009; primary completion date of July 2013
Reported subgroup analyses: not known
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported as double-masked but methods
not known
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported as double-masked but methods
not known
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reported as double-masked but methods
not known
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BRAMD (Continued)
Selective reporting (reporting bias) Unclear risk We searched and collected unpublished
data on death and All SSAE
Other bias Unclear risk Unpublished study with limited informa-
tion available
Adverse event definition Unclear risk Not reported
Method of adverse event assessment Unclear risk Not reported
CATT
Methods Number randomised (total and per group): 1208 participants randomly assigned to
study treatment; number of participants randomised per group not reported
Exclusions after randomisation: 1 study centre (23 participants) was excluded due to
protocol violations
Number analysed (total and per group): 1105 total participants; 284 in ranibizumab
monthly group, 265 in bevacizumab monthly group, 285 in ranibizumab as needed
group, and 271 in bevacizumab as needed group
Unit of analysis: individuals (1 study eye per participant)
Losses to follow-up: 80 total participants: 17 in ranibizumab monthly group (4 died
and 13 with missing data), 21 in bevacizumab monthly group (4 died and 17 with
missing data), 13 in ranibizumab as needed group (5 died and 8 with missing data), and
29 in bevacizumab as needed group (11 died and 18 with missing data)
Compliance: limited information given: mean of 11.7 treatments given for ranibizumab
monthly group and mean of 11.9 treatments given for bevacizumab monthly group
Intention-to-treat analysis: no, 103 participants enrolled and randomised were not
included in the analyses
Reported power calculation: yes, sample of 277 participants per group for power of
90%
Unusual study design: non-inferiority design, 4 arms, 6 pairwise comparisons planned;
at 1 year, participants in themonthly dose treatment groups were re-randomised to either
continue with monthly injections or switch to as needed injections of the same treatment
drug
Participants Country: USA
Age:meanwas 79 years in ranibizumabmonthly group, 80 years in bevacizumabmonthly
group, 78 years in ranibizumab as needed group, and 79 years in bevacizumab as needed
group
Gender (per cent): 732/1185 (61.8%) women and 453/1185 (38.2%) men
Inclusion criteria: age 50 or older; 1 study eye per participant with untreated active
CNV due to AMD (based on presence of leakage as seen by fluorescein angiography and
of fluid as seen by OCT); VA of 20/25 to 20/320 on electronic visual acuity testing
Exclusion criteria: fibrosis or atrophy in centre of fovea in the study eye; CNV in either
eye due to other causes; retinal pigment epithelial tear involving the macula; any concur-
rent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that,
in the opinion of the investigator, could either require medical or surgical intervention
or contribute to VA loss during the 3-year follow-up period; active or recent (within 4
28Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CATT (Continued)
weeks) intraocular inflammation; current vitreous haemorrhage in the study eye; history
of rhegmatogenous retinal detachment or macular hole; active infectious conjunctivi-
tis, keratitis, scleritis, or endophthalmitis; spherical equivalent > 8 dioptres; intraocu-
lar surgery (including cataract surgery) in the study eye within 2 months; uncontrolled
glaucoma; participants unable to be photographed to document CNV, due to known
allergy to fluorescein dye, lack of venous access or cataract obscuring the CNV; pre-
menopausal women not using adequate contraception; pregnancy or lactation; history
of other disease, metabolic dysfunction, physical examination finding, or clinical labo-
ratory finding giving reasonable suspicion of a disease or condition that contraindicates
the use an investigational drug or that might affect interpretation of the results of the
study or render the subject at high risk for treatment complications; current treatment
for active systemic infection; uncontrolled concomitant diseases such as cardiovascular
disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disor-
ders; history of recurrent significant infections or bacterial infections; inability to comply
with study or follow-up procedures
Equivalence of baseline characteristics: a slightly higher percentage of participants in
bevacizumab monthly group had history of transient ischaemic attack (8.7% compared
with 4% in ranibizumab monthly group, 4% in ranibizumab as needed group, and 6.
3% in bevacizumab as needed group)
Diagnoses in participants: 688/1185 (58%) had active neovascular AMDwith CNV in
foveal centre; 315/1185 (27%)hadfluid in foveal centre; 93/1185 (8%)hadhaemorrhage
in foveal centre; 71/1185 (6%) had other foveal centre involvement; and 18/1185 (1.
5%) had no CNV or not possible to grade
History of cardiovascular events at baseline: (bevacizumab, ranibizumab): MI 10.9%,
13%; stroke 6%, 5.8%; TIA 4%, 7.5%
Interventions Intervention 1: 0.5 mg intravitreal ranibizumab on a fixed schedule of every 4 weeks
for 1 year, at 1 year, re-randomisation to ranibizumab every 4 weeks or as needed
Intervention 2: 1.25 mg intravitreal bevacizumab on a fixed schedule of every 4 weeks
for 1 year, at 1 year, re-randomisation to bevacizumab every 4 weeks or as needed
Intervention 3: 0.5 mg intravitreal ranibizumab as needed for 2 years
Intervention 4: 1.25 mg intravitreal bevacizumab as needed for 2 years
Length of follow-up:
Planned: 12 months for primary analysis; 24 months for secondary analyses, with mod-
ifications to 2 intervention arms as described above
Actual: 12 months for primary analysis; 24 months for secondary analyses
Outcomes Primary outcome, as defined: change in visual acuity from baseline at 12 months with
a non-inferiority margin of 5 letters
Secondary outcomes: proportion of eyes with 15-letter change, number of injections,
OCT measured change in foveal thickness, change in lesion size on OCT and also on
fluorescein angiography, incidence of ocular and systemic adverse events, and annual
drug cost
Intervals at which outcome were assessed: weeks 4, 12, 24, 36, 52 during first year for
visual acuity; weeks 4, 8, 12, 24, 52 for changes on OCT
Notes Full study name: Comparison of Age-related macular degeneration Treatment Trials
Type of study: published
Funding: National Eye Institute, National Institutes of Health, US
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CATT (Continued)
Declarations of interest: 1 investigator reported receiving consulting fees from Glaxo-
SmithKline and another consulting fees from Neurotech and SurModics
Study period: accrual February 2008 through December 2009; follow-up through De-
cember 2011
Reported subgroup analyses: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned to 1 of
4 study groups. Randomization schedules
were stratified according to clinical centre
with the use of a permuted-block method
with randomly chosen block sizes.”
Allocation concealment (selection bias) Low risk Web-based data entry system was used to
allocate participants to treatment groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Initially, participants weremasked towhich
drug they received, but not to the treat-
ment schedule. The study investigators
noted that “insurance and billing docu-
ments specified ranibizumabbut not study-
supplied bevacizumab. Therefore, patients
may have learned or deduced their assigned
drug from these financial documents.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Electronic Visual Acuity system (com-
puterised testing) was used for primary
outcome. Retinal centre personnel were
masked. Adverse event reporting was un-
masked, but medical monitor who evalu-
ated serious adverse events was masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7.3% missing data excluding deaths, but
we discussed this issue with the authors and
concluded that active AE monitoring lim-
ited the risk of bias related to missing data
on AEs
Selective reporting (reporting bias) Low risk Reported outcomes: published data on
death and All SSAE
Other bias Low risk Primary and secondary outcomes, specified
a priori, for 1 year of follow-up were re-
ported
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CATT (Continued)
Adverse event definition Low risk Pre-specified, MedDRA reporting system
adopted
Method of adverse event assessment Low risk Active monitoring of AEs
GEFAL
Methods Number randomised (total and per group): 501 participants randomly assigned to
study treatment; 255 in bevacizumab group and 246 in ranibizumab group
Exclusions after randomisation: 16 participants excluded because they received no
injection (9 in bevacizumab group and 7 in ranibizumab group)
Number analysed (total and per group): 485 participants (246 in bevacizumab group
and 239 in ranibizumab group) for safety analysis at 1 year; 404 participants (207 in
bevacizumab group and 197 in ranibizumab group) for analysis on visual acuity at 1
year; most data analysed for 374 participants (191 in bevacizumab group and 183 in
ranibizumab group) with available baseline BCVA data, at least 10 months follow-up,
and did not have major deviations from the study protocol
Unit of analysis: individuals (1 study eye per participant)
Losses to follow-up: 81 total participants: 39 in bevacizumab group and 42 in
ranibizumab group; additional 30 participants (16 in bevacizumab group and 14 in
ranibizumab group) excluded from most analyses due to protocol violations
Compliance: 374/501 participants completed the study without major protocol viola-
tions
Intention-to-treat analysis: no, not all participants enrolled and randomised were in-
cluded in the analyses
Reported power calculation: yes, sample of 200 participants per group for power of
90% to detect 15 letters changes in BCVA
Unusual study design: non-inferiority design
Participants Country: France (38 study centres)
Age: mean age for 374 participants without major protocol violations was 79 years
Gender (per cent): 248/374 (66%) women and 126/374 (34%) men
Inclusion criteria: age 50 or older; active subfoveal neovascular AMD (1 study eye
eligible in bilateral cases); lesion size < 12 disc areas; recent development of lesion in
cases of occult neovessels; BCVA of 20/32 to 20/320 on ETDRS scale
Exclusion criteria: subretinal haemorrhage reaching foveal centre and > 50% of the
lesion area; fibrosis or atrophy in centre of fovea in the study eye; CNV of other patho-
genesis; retinal pigment epithelial tear reaching the macula; previous or current treat-
ment with intravitreal anti-VEGF therapy; history of treatment 3 months prior or in-
traocular surgery 2 months prior to first study injection; history of photocoagulation or
intravitreal medical device in the study eye; ocular or periocular infection; intraocular
inflammation; diabetic retinopathy; history of autoimmune or idiopathic uveitis; IOP≥
25 mmHg with topical hypotensive therapy; aphakia or lack of lens capsule in the study
eye; known illness or condition requiring intraocular surgery within 12 months; known
hypersensitivity to study drugs or allergy to agents used for ocular testing; uncontrolled
arterial hypertension; history of treatment with systemic bevacizumab; premenopausal
women not using adequate contraception; involvement in another clinical study; not
part of French national health insurance programme
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GEFAL (Continued)
Equivalence of baseline characteristics: yes
Diagnoses in participants: 354/374 (95%) had intraretinal and/or subretinal fluid on
OCT
History of cardiovascular events at baseline: (bevacizumab, ranibizumab): hyperten-
sion: 62.3%,51.4%; MI 5.2%, 1.6%; stroke 3.7%, 3.7%; TIA 0.5%, 0%
Interventions Intervention 1: 1.25 mg intravitreal bevacizumab every month for first 3 months; re-
treatment afterwards based on OCT or VA changes
Intervention 2: 0.50 mg intravitreal ranibizumab every month for first 3 months; re-
treatment afterwards based on OCT or VA changes
Length of follow-up:
Planned: 1 year
Actual: 1 year
Outcomes Primary outcome, as defined:mean change in BCVA at 1 year (at least 10 months after
inclusion), as measured on an ETDRS chart
Secondary outcomes, as defined in published reports: visual acuity outcomes at 1
year: BCVA, change in BCVA, proportion with gain of ≥ 15 letters, proportion with
loss of ≥ 15 letters, proportion with gain of ≥ 5 letters, proportion with loss of ≥
5 letters; change in CNV area between the baseline and final evaluations; presence of
intraretinal and/or subretinal fluid; presence of pigment epithelial detachment; central
subfield macular thickness; change in central subfield macular thickness; dye leakage on
angiogram; number of injections; model of OCT equipment; adverse events
Secondary outcomes, as defined in trial registry: efficacy of treatments at 1 year;
proportions of ocular and systemic adverse events at 1 year; average number of injections
and time before re-injection during 1 year; drug profiles in blood and aqueous humor
of a subset of 20 participants at 3 months; medico-economic impact of treatments at 1
year
Intervals at which outcome were assessed: monthly through 12 months
Notes Full study name: Groupe d’Etude Français Avastin versus Lucentis dans la DMLA
néovasculaire
Type of study: published
Funding sources: French Ministry of Health (Programme Hospitalier de Recherche
Clinique National 2008); the French Health Insurance System co-financed the study
and funded study drugs
Declarations of interest: 4 authors declared disclosures as principal investigators for
trials sponsored by Novartis, Bausch & Lomb, Théa, and Alcon; serving on advisory
boards for Alcon, Allergan, Bayer, Bausch & Lomb, Novartis, and Théa; receiving lecture
fees from Alcon, Allergan, Bayer, Bausch & Lomb, Heidelberg Engineering, the Krys
group, Novartis, Théa, and Zeiss; receiving consulting fees from Novartis, Bayer, and
Allergan; or receiving honoraria from Novartis, Bayer, and Allergan; the other 4 authors
declared no conflicts of interests
Study period: random enrolment 24 June 2009 to 9 November 2011
Reported subgroup analyses: none
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “The randomization was stratified by cen-
tre and visual acuity (threshold: 20/100).
Local hospital pharmacies were responsible
for randomizing patients in each centre us-
ing pre-established lists.”’
Allocation concealment (selection bias) Low risk Randomisation was controlled by the phar-
macy service and was not accessible to in-
vestigators (authors’ communication)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical syringes were masked and de-
livered by local hospital pharmacies after
aseptic preparation in authorized, central-
ized drug-preparation units, using vials of
Avastin 100 mg/ml and Lucentis 10 mg/
ml.”
“The main strength of the GEFAL trial is
that the study remained effectively double-
masked, unlike CATT in which some par-
ticipants received billing information and
IVAN in which the masking differed be-
tween centres (some treating teams were
aware of treatment allocation).”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking of outcome assessors achieved (au-
thors’ communication)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4.3% missing data excluding deaths
Selective reporting (reporting bias) Low risk Reported outcomes: published data on
death and All SSAE
Other bias Low risk Differences in outcomes between the trial
registration and published 1-year results
papers included:
1) secondary visual acuity and morphology
outcomes were specified clearly in the pa-
per, but only described as ’efficacy of treat-
ments’ in the trial registration
2) the published paper included model of
OCT equipment as outcome, whereas the
trial registration did not
3) the trial registration included time before
re-injection during 1 year, drug profiles in
blood and aqueous humor of a subset of 20
participants at 3 months, and medico-eco-
nomic impact of treatments as outcomes,
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whereas the published paper did not
Adverse event definition Low risk Pre-specified, MedDRA reporting system
adopted
Method of adverse event assessment Low risk Active monitoring of AEs
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Methods Number randomised (total and per group):
Drug randomisation: 628 total participants; 323 to ranibizumab group and 305 to
bevacizumab group
Regimen randomisation: 312/323 in ranibizumab group and 294/305 in bevacizumab
group completed first 3 injections and were randomised to continue or discontinue
treatment: 157 continued ranibizumab; 155 discontinued ranibizumab; 149 continued
bevacizumab; and 145 discontinued bevacizumab
Exclusions after randomisation: 18 participants did not receive treatment and were
excluded after randomisation to drug treatment (9 in ranibizumab group and 9 in beva-
cizumab group)
Number analysed (total and per group):
At 1-year follow-up: 561 total participants at 1 year; 141 in continued ranibizumab
group; 146 in discontinued ranibizumab group; 136 in continued bevacizumab group;
and 138 in discontinued bevacizumab group
At 2-year follow-up: 525 total participants at 1 year; 134 in continued ranibizumab
group; 137 in discontinued ranibizumab group; 127 in continued bevacizumab group;
and 127 in discontinued bevacizumab group
Unit of analysis: individuals (1 study eye per participant)
Losses to follow-up:
At 1-year follow-up: 49 total participants: 4 participants receiving treatment withdrew
prior to completing third injection (2 in ranibizumab group and 2 in bevacizumab
group); 45 participants randomised to regimen groups exited trial before 1 year (16 in
continued ranibizumab group; 9 in discontinued ranibizumab group; 13 in continued
bevacizumab group; and 7 in discontinued bevacizumab group)
At 2-year follow-up: 85 total participants: 5 participants receiving treatment withdrew
prior to completing third injection (2 in ranibizumab group and 3 in bevacizumab
group); 80 participants randomised to regimen groups exited trial before 2 years (23 in
continued ranibizumab group; 18 in discontinued ranibizumab group; 21 in continued
bevacizumab group; and 18 in discontinued bevacizumab group)
Compliance: the wrong study drug was administered twice during the first year:
At 1-year follow-up: adherence was 6576/6699 (98%) scheduled injections received
At 2-year follow-up: adherence was 12761/14640 (87%) scheduled injections received
Intention-to-treat analysis: no, 67 participants enrolled and randomised were not in-
cluded in the analyses at 1 year and 103 at 2 years
Reported power calculation: yes, sample of 600 participants per group for power of
90% to detect non-inferiority
Unusual study design: non-inferiority design; 2 x 2 factorial design - randomisation
in 2 stages: first randomised to drug treatment (ranibizumab or bevacizumab), then
to treatment regimen (continue monthly injections or discontinue monthly injections
and switch to as needed injections given in 3-month cycles); results reported only as
ranibizumab versus bevacizumab and continuous versus discontinuous
Participants Country: UK (23 study centres)
Age: mean age for 610 participants receiving treatment was 78 years
Gender (per cent): 366/610 (60%) women and 244/610 (40%) men
Inclusion criteria: age 50 or older; previously untreated neovascular AMD in study eye
with any component of the neovascular lesion (CNV, blood, serous pigment epithelial
detachment, elevated blocked fluorescence) involving the centre of the fovea, confirmed
by fluorescein angiography; BCVAof 25 letters or greater on the ETDRS chart (measured
at 1 metre)
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Exclusion criteria: neovascular lesion of 50% or more fibrosis or blood; more than 12
disc diameters; argon laser treatment in study eye within 6 months; presence of thick
blood involving the centre of the fovea; presence of other active ocular disease causing
concurrent vision loss; myopia 8 or more dioptres; previous treatment with PDT or a
VEGF inhibitor in study eye; women pregnant, lactating, or of child bearing potential;
men with a spouse or partner of child bearing potential
Equivalence of baseline characteristics: yes
Diagnoses in participants: 301/610 (58%) had neovascular AMD with CNV in foveal
centre; 308/610 (54%) had fluid in foveal centre; 90/610 (16%) had haemorrhage in
foveal centre; 75/610 (13%) had other foveal centre involvement; and 15/610 (3%) had
no CNV or not possible to grade
History of cardiovascular events at baseline (bevacizumab, ranibizumab): hypertension
not reported, MI 7.4%, 7.6%, stroke 2.2%, 2.3%, TIA 6.4%, 3%
Interventions Intervention 1: 0.5 mg intravitreal ranibizumab monthly for 2 years
Intervention 2: 1.25 mg intravitreal bevacizumab monthly for 2 years
Intervention 3: after first 3monthly 0.5mg intravitreal ranibizumab injections,monthly
treatment was discontinued and treatment was given as needed in cycles of 3 monthly
doses
Intervention 4: after first 3 monthly 1.25 mg intravitreal bevacizumab injections,
monthly treatment was discontinued and treatment was given as needed in cycles of 3
monthly doses
Length of follow-up:
Planned: 2 years
Actual: 2 years
Outcomes Primary outcome, as defined: best corrected distance visual acuity measured as ETDRS
letters at 2 years
Secondary outcomes, as defined in protocol: at 1-year and 2-year follow-up - frequen-
cies of adverse effects of treatment; generic and vision-specific health-related quality of
life; treatment satisfaction; cumulative resource use/cost and cost-effectiveness; clinical
measures of vision (contrast sensitivity measured with Pelli-Robson charts, near visual
acuity measured by Bailey-Love near reading cards, and reading speed measured with
Belfast reading charts); lesion morphology (fluorescein angiography and OCT); distance
visual acuity at 1 year; survival free from treatment failure
Exploratory analysis: association between serum markers and cardiovascular serious
adverse events
Intervals at which outcome were assessed: monthly through 24 months; various data
were collected at every visit depending on assessment schedule and regimen group
Notes Full study name: alternative treatments to Inhibit VEGF in Age-related choroidal Neo-
vascularisation
Type of study: published
Funding sources:National Institute forHealthResearchHealth Technology Assessment
programme, UK
Declarations of interest: various authors reported being principal investigators of tri-
als sponsored by Novartis; attending and being remunerated for attendance at advisory
boards for Novartis, Bayer, Neovista, Oraya, Allergan, and/or Bausch and Lomb; be-
ing employed by institution that has received payments from Novartis, Bayer, Neovista,
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Oraya, Alcon, and/or Pfizer; receiving honoraria from Novartis for lecture and/or teach-
ing fees from Janssen-Cilag
Study period: random enrolment 27 March 2008 to 15 October 2010
Reported subgroup analyses: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomised allocations were computer
generated by a third party in blocks and
stratified by centre.”
“Randomisation was stratified by centre
and was blocked to ensure roughly equal
numbers of participants per group within
a centre.”
Allocation concealment (selection bias) Low risk “Research teams at sites recruited partici-
pants, and accessed a password-protected
website to randomize participants. Alloca-
tions were concealed until participants’ el-
igibility and identities were confirmed.”
“Allocations were computer generated and
concealed with an internet-based system
(Sealed Envelope, London, UK). Staff in
participating centres accessed the website
and, on entering information to confirm
a participant’s identity and eligibility, were
provided with the unique study number.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk From study protocol:
“Participants, clinicians and trial personnel
will be masked to the VEGF inhibitor to
which a participant is assigned.”
“We have chosen not to mask participants,
clinicians and trial personnel to whether
patients are allocated to continue or stop
treatment at 3 months.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “We intended that drug allocation should
be concealed by having separate masked
assessment and unmasked treating teams.
This system was achieved by 14 sites. At
the other 9 sites, staffing levels could not
support this system and an unmasked staff
member prepared ranibizumab in a syringe
identical to those containing bevacizumab
and did not perform assessments.”
“Lesion morphology was assessed by inde-
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pendent graders masked to drug and treat-
ment regimen.”
From study protocol:
“We have chosen not to mask participants,
clinicians and trial personnel to whether
patients are allocated to continue or stop
treatment at 3 months.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13.8% missing data at 2 years excluding
deaths. After discussion with trial authors,
we concluded that active AE monitoring
limited the risk of bias related to missing
data on AEs
Selective reporting (reporting bias) Unclear risk Reported outcomes: published data on
death and All SSAE
Other bias Low risk Differences between the protocol and pub-
lished 1-year and 2-year results papers in-
cluded:
1) 2 secondary outcomes in the protocol
were not listed in the paper: treatment sat-
isfaction and survival free from treatment
failure; and
2) exploratory (serum) analysis in protocol
upgraded to a secondary outcome in paper
Adverse event definition Low risk Pre-specified, MedDRA reporting system
adopted
Method of adverse event assessment Low risk Active monitoring of AEs
LUCAS
Methods Number randomised (total and per group): 420 participants
Exclusions after randomisation: not known
Number analysed (total and per group): 218 to 0.5 mg ranibizumab group, and 2014
to bevacizumab 1.25 mg
Unit of analysis: not known
Losses to follow-up: not known
Compliance: “more than 90% of patients in each treatment group remained in the study
at 12 months, and approximately 80 to 90% remained at 24 months”
Intention-to-treat analysis: not known
Reported power calculation: not known
Unusual study design: none known
Participants Country: Norway
Age: not known
Gender (per cent): not known
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Inclusion criteria: age 50 or older; unilateral or bilateral neovascular AMD (1 study eye
eligible in bilateral cases); untreated CNV including retinal angiomatous proliferation,
with oedema involving the fovea as assessed by fluorescein angiography andOCT; BCVA
of 20/25 to 20/320
Exclusion criteria: subretinal haemorrhage and/or fibrosis involving ≥ 50% of the
lesion area; CNV of other pathogenesis; previous treatment for CNV; history of anti-
VEGF treatment in non-study eye within 4 weeks; intraocular surgery or laser treatment
within 3 months; infection in either eye; active uveitis or intraocular inflammation;
retinal disease that may lead to vision loss in the study eye; impaired visualisation of
the retina precluding adequate diagnosis; IOP ≥ 25 mmHg or uncontrolled glaucoma;
cataract requiring surgery within 2 years; history of treatment with systemic anti-VEGF
drugs; premenopausal women not using adequate contraception or nursing; mentally
or physically unable to participate; serious disease with probability of death during the
study; involvement in another clinical study or use of investigational drugs involving the
macula in the study eye
Equivalence of baseline characteristics: not known
Diagnoses in participants: not known
Interventions Intervention 1: 25 mg/ml intravitreal bevacizumab administered following the “inject
and extend” principle
Intervention 2: 10 mg/ml intravitreal ranibizumab administered following the “inject
and extend” principle
Length of follow-up: 2 years
Outcomes Primaryoutcomes, as defined:mean change in visual acuity at 1 and2 years, asmeasured
on an ETDRS chart (non-inferiority limit of 5 letters)
Secondary outcomes, as defined: number of treatments at 1 and 2 years; proportions
of participants losing fewer than 15 letters at 1 and 2 years, as measured on an ETDRS
chart; macular morphology at 2 years, as measured by fluorescein angiography andOCT;
adverse events at 2 years; number of non-responders at 2 years
Adverse events:classification used not known
Safety assessments: not known
Intervals at which outcome assessed: not known
Notes Full study name: Lucentis Compared to Avastin Study (LUCAS)
Type of study: unpublished (oral communication, American Academy of Ophthalmol-
ogy)
Funding sources: Ullevaal University Hospital, Norway
Declarations of interest: not available
Study period:March 2009; primary completion date of July 2013
Reported subgroup analyses: not known
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
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Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported as double-masked but methods
not known
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported as double-masked but methods
not known
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reported as double-masked but methods
not known
Selective reporting (reporting bias) Unclear risk Unpublished data on death. We searched
and derived data for All SSAE
Other bias Unclear risk Unpublished study with limited informa-
tion available
Adverse event definition Unclear risk Not reported
Method of adverse event assessment Unclear risk Not reported
MANTA
Methods Number randomised (total and per group): 321 participants randomly assigned to
study treatment; number per group not reported
Exclusions after randomisation: 4 participants (3 due to receiving the wrong drug and
1 because the participant received prior treatment and was not eligible)
Number analysed (total and per group): 317 total participants; 154 in bevacizumab
group and 163 in ranibizumab group
Unit of analysis: individuals (1 study eye per participant)
Losses to follow-up: 69 participants: reasons for losses to follow-up not reported (33 in
bevacizumab group, 36 in ranibizumab group)
Compliance: 248/317 participants completed the study
Intention-to-treat analysis: no, 4 participants enrolled and randomised were not in-
cluded in analysis; data imputed using last observation carried forward method for 69
participants lost to follow-up
Reported power calculation: yes, sample of 320 participants, “95% power to detect
a significant difference between ranibizumab and bevacizumab assuming a seven letters
increase in visual acuity with ranibizumab and no change in visual acuity with beva-
cizumab”. The assumption of no change in visual acuity with bevacizumab is unrealistic
Unusual study design: non-inferiority design
Participants Country: 10 clinical centres in Austria
Age: mean 76.7 years in bevacizumab group and 77.6 years in ranibizumab group
Gender (per cent): 115/317 (36.3%) men and 202/317 (63.7%) women
Inclusion criteria: age 50 or older; active primary or recurrent subfoveal lesion with
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CNV, measured by fluorescein angiography or OCT; BCVA in study eye between 20/
40 to 20/320, measured by ETDRS charts
Exclusion criteria: previous treatment for CNV or AMD; prior treatment with any
intravitreal drug or verteporfin PDT in study eye; prior treatment with systemic beva-
cizumab; prior treatment with any intravitreal drug or verteporfin PDT in non-study
eye within 3 months; laser photocoagulation in study eye within 1 month; participation
in another clinical trial within 1 month; subfoveal fibrosis or atrophy > 50% in study
eye; CNV in either eye due other causes than AMD; RPE tear involving macula of study
eye; history of uncontrolled glaucoma or concurrent intraocular condition in study eye;
pregnancy; allergy to fluorescein; inability to comply with study procedures
Equivalence of baseline characteristics: yes
Diagnoses in participants: active primary or recurrent subfoveal CNV
History of cardiovascular events at baseline (bevacizumab, ranibizumab): participants
with severe hypertension, MI, stroke, TIA were excluded
Interventions Intervention 1: 1.25 mg intravitreal bevacizumab every month for first 3 months; re-
treatment afterwards based on OCT or VA changes
Intervention 2: 0.5 mg intravitreal ranibizumab every month for first 3 months; re-
treatment afterwards based on OCT or VA changes
Length of follow-up:
Planned: 12 months
Actual: 12 months
Outcomes Primary outcomes, as defined: “mean change in BCVA between baseline and 1 year”
Secondary outcomes, as reported: Kaplan-Meier proportions of the gain of 15 letters
of vision, gain of 5 letters of vision, loss of 5 letters of vision, loss of 15 letters of vision;
lesion size, assessed by fluorescein angiography; number of re-treatments; and retinal
thickness, assessed by OCT
Adverse events: classification method definition not reported
Intervals at which outcome assessed: monthly through 12 months
Notes Full study name: A Randomized Observer and Subject Masked Trial Comparing the
Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With
Neovascular Age-relatedMacular Degeneration Multicentre Anti VEGF Trial in Austria
Type of study: published
Funding sources: Austrian ophthalmologic society; the Ludwig Boltzmann Institute of
Retinology and Biomicroscopic Lasersurgery; the participating study centre sites
Declarations of interest: authors reported no competing interests
Study period: not reported
Reported subgroup analyses: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was stratified according to
the clinical centre using a permuted block
method with a fixed block size of 20.”
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Allocation concealment (selection bias) Low risk “Eligible patients were randomised in a 1:1
ratio to one of two groups by members of
the Department of Clinical Pharmacology,
Medical University of Vienna, which was
otherwise not involved in the study.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All other personnel and the patients were
masked to treatment assignment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The evaluating physician was masked to
treatment assignment, whereas the inject-
ing physician was not involved in the col-
lection of data.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 21.5% missing visual acuity data at 1 year.
Active monitoring of adverse events might
have limited the risk of bias related to miss-
ing data on adverse events
Selective reporting (reporting bias) Low risk Reported outcomes: published data on
death and All SSAE
Other bias Low risk None observed
Adverse event definition Unclear risk Not reported
Method of adverse event assessment Unclear risk Not reported
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Methods Number randomised (total and per group): 28 participants randomly assigned to study
treatment; 20 in bevacizumab group and 8 in ranibizumab group
Exclusions after randomisation: none
Number analysed (total and per group): 22 total participants; 15 in bevacizumab
group and 7 in ranibizumab group
Unit of analysis: individuals (1 study eye per participant)
Losses to follow-up: 6 participants: 3 participants voluntarily dropped out (2 in beva-
cizumab group, 1 in ranibizumab group); 1 participant relocated (in bevacizumab group)
; and 2 participants died (both in bevacizumab group)
Compliance: 22/28 participants completed the study
Intention-to-treat analysis: no, 6 participants enrolled and randomised were not in-
cluded in analysis
Reported power calculation: yes, 79%power for sample size of 135 participants using 2:
1 randomisation ratio. However, the number of enrolled participants seem not adequate
to detect differences in adverse events
Unusual study design: although the target sample size was 135, only 28 participants
were evaluated
Participants Country: Boston, MA, USA
Age: not reported for 28 enrolled participants (mean 78 years for analysed bevacizumab
group; mean 80 years for analysed ranibizumab group)
Gender (per cent): not reported for 28 enrolled participants (all men for analysed
bevacizumab group; 6 men and 1 woman for analysed ranibizumab group)
Inclusion criteria: age 50 or older; presence of symptomatic CNV, confirmed by intra-
venous fluorescein angiogram and optical coherence tomography as affecting the foveal
centre; ability to provide informed consent; willing to commit to regular clinic appoint-
ments and follow-up; original protocol specified baseline VA between 20/40 and 20/
200, later amended to include all baseline VAs equal to or better than 20/400
Exclusion criteria: previous treatment for wet AMD within the past year; presence of
subretinal haemorrhage greater than 50% of the size of the lesion on fluorescein angiog-
raphy, presence of advanced glaucoma; any coexisting macular disease causing decreased
vision; history of malignant or uncontrolled hypertension; intraocular inflammation;
history of thromboembolic phenomena; inability to provide informed consent; partici-
pation in another concurrent ophthalmic clinical trial
Equivalence of baseline characteristics: yes
Diagnoses in participants: AMD
Interventions Intervention 1: 0.05 ml intravitreal bevacizumab every month for first 3 months; re-
treatment afterwards based on OCT or VA changes
Intervention 2: 0.05 ml intravitreal ranibizumab every month for first 3 months; re-
treatment afterwards based on OCT or VA changes
Length of follow-up:
Planned: 12 months
Actual: 12 months
Outcomes Primary outcomes, as defined: visual acuity
Secondary outcomes, as reported: central foveal thickness by OCT, total number of
injections; blood pressure measurements
Adverse events
Intervals at which outcome assessed: 1 week after injections to assess adverse events;
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and monthly through 12 months
Notes Type of study: published
Funding sources: Veterans Affairs Boston Healthcare System, USA
Declarations of interest: “The authors declare no conflict of interest”
Study period: April 2007 to February 2009
Reported subgroup analyses: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were enrolled by a 2:1 random-
ization to either the bevacizumab (2) or the
ranibizumab (1) arm of the study.” Study
investigators were contacted, but could not
provide additional information as to how
the sequence was generated (email commu-
nication with Dr. Subramanian, dated 16
May 2012)
Allocation concealment (selection bias) Low risk “The Research Pharmacist at the [Veterans
Affairs]Hospital Pharmacywas responsible
for randomization” and “all subjects were
assigned a study number.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as “double-blind”; identical sy-
ringes were used to administer agents, and
study personnel in contact with partici-
pants were all masked
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “As the only investigator with knowledge
of subject assignments, the Research Phar-
macist was, in turn, masked to all visual
and anatomic outcomes to treatment. All
other investigators, as well as other physi-
cians, residents, and office personnel who
may have inadvertently come in contact
with study subjects, were masked to treat-
ment assignments.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 of 28 (21%) participants enrolled were
not included in the analysis: 3 voluntarily
dropped out; 1 relocated; and 2 died
Selective reporting (reporting bias) Unclear risk Reported outcomes: published data on
death and All SSAE
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Other bias Unclear risk Quality of life reported as an outcome in
the clinical trials register but not reported
in the full-text publication
Trial stopped early for poor recruitment.
Stopping characteristics:
- Interim analyses: after the first 28 partic-
ipants enrolled (sample size planned 135
participants)
- Details of stop: “From April 2007 to
February 2009, 28 patients were enrolled
in the study. This relatively low number of
patients enrolled over a 2-year period was
likely due to two reasons. A larger than ex-
pected number of potential study partici-
pants was previously treated with visudyne
or other anti-angiogenesis agentswithin the
past 12 months, thus disqualifying them
from the study. There was also a lower vol-
ume of AMDpatients who presented to the
Veterans Affairs and met inclusion crite-
ria than initially anticipated. Both of these
factors contributed to low enrolment. All
those who met inclusion criteria were of-
fered enrolment in the study, and a rela-
tively high number (estimated 80%) con-
sented to participation.”
Adverse event definition Unclear risk Not reported
Method of adverse event assessment Unclear risk Not reported
VIBERA
Methods Number randomised (total and per group): 161 participants (107 bevacizumab and
54 ranibizumab)
Exclusions after randomisation: 5
Number analysed (total and per group): 142, 47 to 0.5 mg ranibizumab group, and
95 to bevacizumab 1.25 mg
Unit of analysis: individuals (1 study eye per participant)
Losses to follow-up: none
Compliance: high
Intention-to-treat analysis: no, 142 participants included in the per protocol analysis
Reported power calculation: 90% (7 ETDRS letters)
Unusual study design: no
Participants Country: Germany
Age: mean age 77 years
Gender (per cent): female 62%
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Inclusion criteria: age 50 or older; visual impairment due to active primary or recur-
rent CNV associated with AMD; classical or predominantly classic lesion with largest
diameter of the subretinal neovascular membrane smaller than greatest distance between
major temporal vascular arcades, minimally classic lesion, or occult lesion with no classic
CNV; BCVA of 20/40 to 20/320
Exclusion criteria: subretinal haemorrhage involving ≥ 50% of the lesion area or ≥
1 optic disc areas; subfoveal fibrosis or atrophy; CNV of other pathogenesis; previous
treatment for CNV or treatment with any anti-angiogenic drugs; previous intravitreal
drug delivery, laser photocoagulation, vitreoretinal surgery, submacular surgery, or other
surgical intervention for AMD in the study eye; retinal pigment epithelial tear; active
inflammation, vitreous haemorrhage, infectious conjunctivitis, keratitis, scleritis, or en-
dophthalmitis; history of rhegmatogenous retinal detachment, macular hole, idiopathic
or autoimmune-associated uveitis, or corneal transplant; aphakia or lack of posterior
capsule in the study eye; > -8 dioptres of myopia; any intraocular condition that re-
quires surgery or could lead to vision loss within 2 years; intraocular surgery in study eye
within 2 months; uncontrolled glaucoma or history of glaucoma filtering surgery; im-
paired visualisation of the retina precluding adequate diagnosis; premenopausal women
not using adequate contraception or nursing; active systemic infection or other disease,
dysfunction, or finding to contraindicate participation; hypersensitivity to study drugs
or allergy to agents used for ocular testing; involvement in another clinical study within
4 weeks; unwillingness or inability to comply with study
Equivalence of baseline characteristics: yes; no significant differences observed
Diagnoses in participants:MI none, stroke: 1 (ranibizumab), TIA none
Interventions Intervention 1: 1.25 mg intravitreal bevacizumab administered monthly or on demand
Intervention 2: 0.5 mg intravitreal ranibizumab administered monthly or on demand
Length of follow-up: 1 year
Outcomes Primary outcomes, as defined: mean change in BCVA at 1 year, as measured on an
ETDRS chart
Secondary outcomes, as defined: proportion of participants losing fewer than 15 letters
at 2 years; proportion of participants with at least 3 months treatment-free in 2 years;
number of doses of study drugs at 2 years; rate of drop-out at 2 years; number of non-
responders at 2 years; retinal lesions at 2 years; adverse events at 2 years; quality of life at
2 years
Adverse events: pre-specified, MedDRA reporting system
Safety assessments: adverse events at 1 year
Intervals at which outcome assessed: monthly
Notes Full study name: Prevention of Vision Loss in Patients With Age-Related Macu-
lar Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
(VIBERA)
Type of study: unpublished (first authors’ personal communication)
Funding sources: Deutsche Stiftung für Chronisch Kranke (http://www.dsck.de)
Declarations of interest:
1 author declared no conflict of interest. 1 author declared disclosures for grants by the
Deutsche Stiftung für Chronisch Kranke, Institutions of the German Health System
(statutory health insurance, German Physicians Association)
Study period:August 2009; primary completion date of August 2012; study interrupted
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early due to loss of study medication production site
Reported subgroup analyses: not performed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 2:1 randomisation, blockwise (by study
site) randomisation computer-generated in
the Department of Statistics
Allocation concealment (selection bias) Low risk Allocation list not accessible for study per-
sonnel nor participants, information on the
allocation code exclusively kept in the De-
partment of Statistics
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Allocation information not accessible for
participants nor study personnel; identical-
looking study medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Allocation information not accessible for
participants nor study personnel; identical-
looking study medication
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 particpants excluded because of missing
data at start or 1 year. No loss to follow-up.
All drop-outs medically clarified
Selective reporting (reporting bias) Low risk We searched and collected unpublished
data on death and All SSAE
Other bias Low risk All primary and secondary outcomes were
reported
Adverse event definition Low risk Pre-specified, MedDRA reporting system
Method of adverse event assessment Low risk Activemonitoring of AEs: ophthalmologist
saw participants 2 to 3 days after injection,
participants were asked for AEs monthly
and when omitting study visits
AE: adverse event
AMD: age-related macular degeneration
ARVO: Association for Research in Vision and Ophthalmology
BCVA: best corrected visual acuity
CMT: central macular thickness
CNV: choroidal neovascularisation
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ETDRS: Early Treatment Diabetic Retinopathy Study
IOP: intraocular pressure
MedDRA: Medical Dictionary for Regulatory Activities
MI: myocardial infarction
SSAE: serious systemic adverse event
TIA: transient ischaemic attack
VA: visual acuity
VEGF: vascular endothelial growth factor
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D A T A A N D A N A L Y S E S
Comparison 1. Bevacizumab versus ranibizumab, longest follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause death 8 3338 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.78, 1.57]
2 All serious systemic adverse
events
9 3665 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.90, 1.31]
3 Arterial thromboembolic event 6 3190 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.62, 1.37]
4 Gastrointestinal perforation 1 161 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Infection 6 3190 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.97, 1.86]
6 Myocardial infarction 6 3190 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.42, 1.66]
7 Neutropenia 1 161 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Non-ocular haemorrhage 3 1256 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.85]
9 Stroke 6 3190 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.42, 1.66]
10 Treatment-related drug
discontinuation
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Vascular events associated with
anti-VEGF treatment
3 1823 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.52, 2.05]
12 Cardiac disorders MedDRA
Class
4 2441 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.89, 1.61]
13 Gastrointestinal disorders
MedDRA Class
6 3190 Risk Ratio (M-H, Random, 95% CI) 1.82 [1.04, 3.19]
14 General disorders and
administration site conditions
MedDRA Class
3 1256 Risk Ratio (M-H, Random, 95% CI) 1.93 [0.32, 11.65]
15 Neoplasms benign, malignant,
and unspecified MedDRA
Class
6 3190 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.68, 1.46]
16 Nervous system disorders
MedDRA Class
6 3190 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.77, 1.68]
17 Respiratory, thoracic, and
mediastinal disorders MedDRA
Class
3 1256 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.42, 2.12]
Comparison 2. Bevacizumab versus ranibizumab, one-year of follow-up, primary outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause death 7 3218 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.72, 2.10]
2 All serious systemic adverse
events
8 3545 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.90, 1.37]
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Comparison 3. Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding CATT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All serious systemic adverse
events
8 2480 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.82, 1.25]
Comparison 4. Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding LUCAS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All serious systemic adverse
events
8 3233 Risk Ratio (M-H, Random, 95% CI) 1.19 [1.06, 1.34]
Comparison 5. Bevacizumab versus ranibizumab, influence analysis: primary outcomes excluding unpublished
studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause death 6 2745 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.78, 1.62]
2 All serious systemic adverse
events
6 2745 Risk Ratio (M-H, Random, 95% CI) 1.21 [1.06, 1.37]
Comparison 6. Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause death 8 3338 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.78, 1.57]
2 All serious systemic adverse
events
9 3665 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [1.00, 1.26]
3 Arterial thromboembolic event 6 3190 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.62, 1.32]
4 Gastrointestinal perforation 1 161 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Infections 6 3190 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.97, 1.87]
6 Myocardial infarction 6 3190 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.37, 1.35]
7 Neutropenia 1 161 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Non-ocular haemorrhage 3 1256 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.08, 1.50]
9 Stroke 6 3190 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.42, 1.63]
10 Treatment-related drug
discontinuation
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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11 Vascular events associated with
anti-VEGF treatment
3 1823 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.85, 1.56]
12 Cardiac disorders MedDRA
Class
4 2441 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.88, 1.59]
13 Gastrointestinal disorders
MedDRA Class
6 3190 Risk Ratio (M-H, Fixed, 95% CI) 1.93 [1.20, 3.11]
14 General disorders and
administration site conditions
MedDRA Class
3 1256 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.73, 2.65]
15 Neoplasms benign, malignant,
and unspecified MedDRA
Class
6 3190 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.68, 1.46]
16 Nervous system disorders
MedDRA Class
6 3190 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.79, 1.73]
17 Respiratory, thoracic, and
mediastinal disorders MedDRA
Class
3 1256 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.42, 2.12]
Analysis 1.1. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 1 All-cause
death.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 1 All-cause death
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Biswas 2011 0/60 0/60 Not estimable
CATT 36/586 32/599 58.4 % 1.15 [ 0.72, 1.83 ]
GEFAL 2/246 3/239 3.9 % 0.65 [ 0.11, 3.84 ]
IVAN 15/296 15/314 25.6 % 1.06 [ 0.53, 2.13 ]
LUCAS 3/214 3/218 4.9 % 1.02 [ 0.21, 4.99 ]
MANTA 3/154 2/163 4.0 % 1.59 [ 0.27, 9.37 ]
Subramanian 2010 2/20 0/8 1.5 % 2.14 [ 0.11, 40.30 ]
VIBERA 1/107 1/54 1.6 % 0.50 [ 0.03, 7.91 ]
Total (95% CI) 1683 1655 100.0 % 1.10 [ 0.78, 1.57 ]
Total events: 62 (Bevacizumab), 56 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.06, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
More events ranibizumab More events bevacizumab
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Analysis 1.2. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 2 All serious
systemic adverse events.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 2 All serious systemic adverse events
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Biswas 2011 0/60 0/60 Not estimable
BRAMD 34/161 37/166 13.3 % 0.95 [ 0.63, 1.43 ]
CATT 234/586 190/599 29.5 % 1.26 [ 1.08, 1.47 ]
GEFAL 30/246 24/239 10.1 % 1.21 [ 0.73, 2.02 ]
IVAN 80/296 81/314 21.3 % 1.05 [ 0.80, 1.37 ]
LUCAS 33/214 51/218 14.1 % 0.66 [ 0.44, 0.98 ]
MANTA 18/154 15/163 6.9 % 1.27 [ 0.66, 2.43 ]
Subramanian 2010 2/20 0/8 0.4 % 2.14 [ 0.11, 40.30 ]
VIBERA 22/107 6/54 4.4 % 1.85 [ 0.80, 4.29 ]
Total (95% CI) 1844 1821 100.0 % 1.08 [ 0.90, 1.31 ]
Total events: 453 (Bevacizumab), 404 (Ranibizumab)
Heterogeneity: Tau2 = 0.03; Chi2 = 11.78, df = 7 (P = 0.11); I2 =41%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 1.3. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 3 Arterial
thromboembolic event.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 3 Arterial thromboembolic event
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 29/586 28/599 57.2 % 1.06 [ 0.64, 1.76 ]
GEFAL 1/246 1/239 2.1 % 0.97 [ 0.06, 15.44 ]
IVAN 10/296 13/314 23.4 % 0.82 [ 0.36, 1.83 ]
LUCAS 3/214 10/218 9.6 % 0.31 [ 0.09, 1.10 ]
MANTA 5/154 3/163 7.8 % 1.76 [ 0.43, 7.26 ]
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 1603 1587 100.0 % 0.92 [ 0.62, 1.37 ]
Total events: 48 (Bevacizumab), 55 (Ranibizumab)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.07, df = 4 (P = 0.40); I2 =2%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 4
Gastrointestinal perforation.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 4 Gastrointestinal perforation
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 107 54 Not estimable
Total events: 0 (Bevacizumab), 0 (Ranibizumab)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 5 Infection.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 5 Infection
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 54/586 41/599 70.9 % 1.35 [ 0.91, 1.99 ]
GEFAL 4/246 2/239 3.8 % 1.94 [ 0.36, 10.51 ]
IVAN 12/296 9/314 14.9 % 1.41 [ 0.60, 3.31 ]
LUCAS 3/214 4/218 4.9 % 0.76 [ 0.17, 3.37 ]
MANTA 3/154 3/163 4.3 % 1.06 [ 0.22, 5.16 ]
VIBERA 3/107 0/54 1.2 % 3.56 [ 0.19, 67.79 ]
Total (95% CI) 1603 1587 100.0 % 1.34 [ 0.97, 1.86 ]
Total events: 79 (Bevacizumab), 59 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 5 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 6 Myocardial
infarction.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 6 Myocardial infarction
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 7/586 9/599 48.6 % 0.80 [ 0.30, 2.12 ]
GEFAL 1/246 1/239 6.1 % 0.97 [ 0.06, 15.44 ]
IVAN 4/296 4/314 24.7 % 1.06 [ 0.27, 4.20 ]
LUCAS 0/214 6/218 5.7 % 0.08 [ 0.00, 1.38 ]
MANTA 3/154 2/163 14.9 % 1.59 [ 0.27, 9.37 ]
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 1603 1587 100.0 % 0.84 [ 0.42, 1.66 ]
Total events: 15 (Bevacizumab), 22 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.48, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 7 Neutropenia.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 7 Neutropenia
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 107 54 Not estimable
Total events: 0 (Bevacizumab), 0 (Ranibizumab)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 8 Non-ocular
haemorrhage.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 8 Non-ocular haemorrhage
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
GEFAL 0/246 3/239 27.9 % 0.14 [ 0.01, 2.67 ]
IVAN 1/296 3/314 48.0 % 0.35 [ 0.04, 3.38 ]
VIBERA 1/107 0/54 24.1 % 1.53 [ 0.06, 36.89 ]
Total (95% CI) 649 607 100.0 % 0.39 [ 0.08, 1.85 ]
Total events: 2 (Bevacizumab), 6 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.19, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 9 Stroke.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 9 Stroke
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 8/586 8/599 49.6 % 1.02 [ 0.39, 2.71 ]
GEFAL 0/246 0/239 Not estimable
IVAN 3/296 6/314 24.8 % 0.53 [ 0.13, 2.10 ]
LUCAS 2/214 3/218 14.8 % 0.68 [ 0.11, 4.02 ]
MANTA 1/154 1/163 6.2 % 1.06 [ 0.07, 16.77 ]
VIBERA 1/107 0/54 4.6 % 1.53 [ 0.06, 36.89 ]
Total (95% CI) 1603 1587 100.0 % 0.83 [ 0.42, 1.66 ]
Total events: 15 (Bevacizumab), 18 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 11 Vascular
events associated with anti-VEGF treatment.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 11 Vascular events associated with anti-VEGF treatment
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 62/586 45/599 55.6 % 1.41 [ 0.98, 2.03 ]
IVAN 17/296 26/314 44.4 % 0.69 [ 0.38, 1.25 ]
Subramanian 2010 0/20 0/8 Not estimable
Total (95% CI) 902 921 100.0 % 1.03 [ 0.52, 2.05 ]
Total events: 79 (Bevacizumab), 71 (Ranibizumab)
Heterogeneity: Tau2 = 0.19; Chi2 = 3.99, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 12 Cardiac
disorders MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 12 Cardiac disorders MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 62/586 47/599 67.6 % 1.35 [ 0.94, 1.94 ]
GEFAL 2/246 5/239 3.3 % 0.39 [ 0.08, 1.98 ]
IVAN 19/296 20/314 23.9 % 1.01 [ 0.55, 1.85 ]
VIBERA 7/107 3/54 5.1 % 1.18 [ 0.32, 4.37 ]
Total (95% CI) 1235 1206 100.0 % 1.20 [ 0.89, 1.61 ]
Total events: 90 (Bevacizumab), 75 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.56, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 13
Gastrointestinal disorders MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 13 Gastrointestinal disorders MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 28/586 11/599 44.2 % 2.60 [ 1.31, 5.18 ]
GEFAL 3/246 5/239 13.9 % 0.58 [ 0.14, 2.41 ]
IVAN 9/296 3/314 16.4 % 3.18 [ 0.87, 11.64 ]
LUCAS 6/214 5/218 19.5 % 1.22 [ 0.38, 3.95 ]
MANTA 0/154 0/163 Not estimable
VIBERA 3/107 1/54 6.0 % 1.51 [ 0.16, 14.21 ]
Total (95% CI) 1603 1587 100.0 % 1.82 [ 1.04, 3.19 ]
Total events: 49 (Bevacizumab), 25 (Ranibizumab)
Heterogeneity: Tau2 = 0.06; Chi2 = 4.65, df = 4 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.10 (P = 0.035)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 14 General
disorders and administration site conditions MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 14 General disorders and administration site conditions MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
GEFAL 4/246 0/239 26.1 % 8.74 [ 0.47, 161.55 ]
IVAN 16/296 15/314 73.9 % 1.13 [ 0.57, 2.25 ]
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 649 607 100.0 % 1.93 [ 0.32, 11.65 ]
Total events: 20 (Bevacizumab), 15 (Ranibizumab)
Heterogeneity: Tau2 = 1.02; Chi2 = 1.87, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 15 Neoplasms
benign, malignant, and unspecified MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 15 Neoplasms benign, malignant, and unspecified MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 22/586 27/599 48.4 % 0.83 [ 0.48, 1.45 ]
GEFAL 1/246 1/239 1.9 % 0.97 [ 0.06, 15.44 ]
IVAN 14/296 11/314 24.6 % 1.35 [ 0.62, 2.93 ]
LUCAS 10/214 8/218 17.8 % 1.27 [ 0.51, 3.16 ]
MANTA 1/154 2/163 2.6 % 0.53 [ 0.05, 5.78 ]
VIBERA 3/107 2/54 4.8 % 0.76 [ 0.13, 4.40 ]
Total (95% CI) 1603 1587 100.0 % 1.00 [ 0.68, 1.46 ]
Total events: 51 (Bevacizumab), 51 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 5 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 16 Nervous
system disorders MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 16 Nervous system disorders MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 36/586 34/599 74.9 % 1.08 [ 0.69, 1.71 ]
GEFAL 3/246 0/239 1.8 % 6.80 [ 0.35, 130.98 ]
IVAN 8/296 9/314 17.6 % 0.94 [ 0.37, 2.41 ]
LUCAS 1/214 0/218 1.5 % 3.06 [ 0.13, 74.60 ]
MANTA 2/154 1/163 2.7 % 2.12 [ 0.19, 23.11 ]
VIBERA 1/107 0/54 1.5 % 1.53 [ 0.06, 36.89 ]
Total (95% CI) 1603 1587 100.0 % 1.13 [ 0.77, 1.68 ]
Total events: 51 (Bevacizumab), 44 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.29, df = 5 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Bevacizumab versus ranibizumab, longest follow-up, Outcome 17 Respiratory,
thoracic, and mediastinal disorders MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 1 Bevacizumab versus ranibizumab, longest follow-up
Outcome: 17 Respiratory, thoracic, and mediastinal disorders MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
GEFAL 4/246 4/239 34.7 % 0.97 [ 0.25, 3.84 ]
IVAN 7/296 8/314 65.3 % 0.93 [ 0.34, 2.53 ]
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 649 607 100.0 % 0.94 [ 0.42, 2.12 ]
Total events: 11 (Bevacizumab), 12 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Bevacizumab versus ranibizumab, one-year of follow-up, primary outcomes,
Outcome 1 All-cause death.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 2 Bevacizumab versus ranibizumab, one-year of follow-up, primary outcomes
Outcome: 1 All-cause death
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CATT 15/586 9/599 42.7 % 1.70 [ 0.75, 3.86 ]
GEFAL 2/246 3/239 9.0 % 0.65 [ 0.11, 3.84 ]
IVAN 5/296 6/314 20.7 % 0.88 [ 0.27, 2.87 ]
LUCAS 3/214 3/218 11.3 % 1.02 [ 0.21, 4.99 ]
MANTA 3/154 2/163 9.1 % 1.59 [ 0.27, 9.37 ]
Subramanian 2010 2/20 0/8 3.3 % 2.14 [ 0.11, 40.30 ]
VIBERA 1/107 1/54 3.8 % 0.50 [ 0.03, 7.91 ]
Total (95% CI) 1623 1595 100.0 % 1.23 [ 0.72, 2.10 ]
Total events: 31 (Bevacizumab), 24 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.08, df = 6 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Bevacizumab versus ranibizumab, one-year of follow-up, primary outcomes,
Outcome 2 All serious systemic adverse events.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 2 Bevacizumab versus ranibizumab, one-year of follow-up, primary outcomes
Outcome: 2 All serious systemic adverse events
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
BRAMD 34/161 37/166 15.7 % 0.95 [ 0.63, 1.43 ]
CATT 141/586 114/599 27.3 % 1.26 [ 1.02, 1.57 ]
GEFAL 30/246 24/239 12.1 % 1.21 [ 0.73, 2.02 ]
IVAN 37/296 30/314 13.9 % 1.31 [ 0.83, 2.06 ]
LUCAS 33/214 51/218 16.5 % 0.66 [ 0.44, 0.98 ]
MANTA 18/154 15/163 8.4 % 1.27 [ 0.66, 2.43 ]
Subramanian 2010 2/20 0/8 0.5 % 2.14 [ 0.11, 40.30 ]
VIBERA 22/107 6/54 5.5 % 1.85 [ 0.80, 4.29 ]
Total (95% CI) 1784 1761 100.0 % 1.11 [ 0.90, 1.37 ]
Total events: 317 (Bevacizumab), 277 (Ranibizumab)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.97, df = 7 (P = 0.14); I2 =36%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding CATT,
Outcome 1 All serious systemic adverse events.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 3 Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding CATT
Outcome: 1 All serious systemic adverse events
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Biswas 2011 0/60 0/60 Not estimable
BRAMD 34/161 37/166 18.8 % 0.95 [ 0.63, 1.43 ]
GEFAL 30/246 24/239 13.9 % 1.21 [ 0.73, 2.02 ]
IVAN 80/296 81/314 31.8 % 1.05 [ 0.80, 1.37 ]
LUCAS 33/214 51/218 19.9 % 0.66 [ 0.44, 0.98 ]
MANTA 18/154 15/163 9.2 % 1.27 [ 0.66, 2.43 ]
Subramanian 2010 2/20 0/8 0.5 % 2.14 [ 0.11, 40.30 ]
VIBERA 22/107 6/54 5.8 % 1.85 [ 0.80, 4.29 ]
Total (95% CI) 1258 1222 100.0 % 1.01 [ 0.82, 1.25 ]
Total events: 219 (Bevacizumab), 214 (Ranibizumab)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.87, df = 6 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding
LUCAS, Outcome 1 All serious systemic adverse events.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 4 Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding LUCAS
Outcome: 1 All serious systemic adverse events
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Biswas 2011 0/60 0/60 Not estimable
BRAMD 34/161 37/166 8.4 % 0.95 [ 0.63, 1.43 ]
CATT 234/586 190/599 60.2 % 1.26 [ 1.08, 1.47 ]
GEFAL 30/246 24/239 5.6 % 1.21 [ 0.73, 2.02 ]
IVAN 80/296 81/314 20.3 % 1.05 [ 0.80, 1.37 ]
MANTA 18/154 15/163 3.4 % 1.27 [ 0.66, 2.43 ]
Subramanian 2010 2/20 0/8 0.2 % 2.14 [ 0.11, 40.30 ]
VIBERA 22/107 6/54 2.0 % 1.85 [ 0.80, 4.29 ]
Total (95% CI) 1630 1603 100.0 % 1.19 [ 1.06, 1.34 ]
Total events: 420 (Bevacizumab), 353 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.83, df = 6 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Bevacizumab versus ranibizumab, influence analysis: primary outcomes
excluding unpublished studies, Outcome 1 All-cause death.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 5 Bevacizumab versus ranibizumab, influence analysis: primary outcomes excluding unpublished studies
Outcome: 1 All-cause death
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Biswas 2011 0/60 0/60 Not estimable
CATT 36/586 32/599 62.5 % 1.15 [ 0.72, 1.83 ]
GEFAL 2/246 3/239 4.2 % 0.65 [ 0.11, 3.84 ]
IVAN 15/296 15/314 27.5 % 1.06 [ 0.53, 2.13 ]
MANTA 3/154 2/163 4.2 % 1.59 [ 0.27, 9.37 ]
Subramanian 2010 2/20 0/8 1.6 % 2.14 [ 0.11, 40.30 ]
Total (95% CI) 1362 1383 100.0 % 1.12 [ 0.78, 1.62 ]
Total events: 58 (Bevacizumab), 52 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 4 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Bevacizumab versus ranibizumab, influence analysis: primary outcomes
excluding unpublished studies, Outcome 2 All serious systemic adverse events.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 5 Bevacizumab versus ranibizumab, influence analysis: primary outcomes excluding unpublished studies
Outcome: 2 All serious systemic adverse events
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Biswas 2011 0/60 0/60 Not estimable
CATT 234/586 190/599 67.2 % 1.26 [ 1.08, 1.47 ]
GEFAL 30/246 24/239 6.2 % 1.21 [ 0.73, 2.02 ]
IVAN 80/296 81/314 22.6 % 1.05 [ 0.80, 1.37 ]
MANTA 18/154 15/163 3.8 % 1.27 [ 0.66, 2.43 ]
Subramanian 2010 2/20 0/8 0.2 % 2.14 [ 0.11, 40.30 ]
Total (95% CI) 1362 1383 100.0 % 1.21 [ 1.06, 1.37 ]
Total events: 364 (Bevacizumab), 310 (Ranibizumab)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.56, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 1 All-cause death.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 1 All-cause death
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Biswas 2011 0/60 0/60 Not estimable
CATT 36/586 32/599 56.3 % 1.15 [ 0.72, 1.83 ]
GEFAL 2/246 3/239 5.4 % 0.65 [ 0.11, 3.84 ]
IVAN 15/296 15/314 25.9 % 1.06 [ 0.53, 2.13 ]
LUCAS 3/214 3/218 5.3 % 1.02 [ 0.21, 4.99 ]
MANTA 3/154 2/163 3.5 % 1.59 [ 0.27, 9.37 ]
Subramanian 2010 2/20 0/8 1.2 % 2.14 [ 0.11, 40.30 ]
VIBERA 1/107 1/54 2.4 % 0.50 [ 0.03, 7.91 ]
Total (95% CI) 1683 1655 100.0 % 1.10 [ 0.78, 1.57 ]
Total events: 62 (Bevacizumab), 56 (Ranibizumab)
Heterogeneity: Chi2 = 1.06, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 2 All serious systemic adverse events.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 2 All serious systemic adverse events
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Biswas 2011 0/60 0/60 Not estimable
BRAMD 34/161 37/166 9.1 % 0.95 [ 0.63, 1.43 ]
CATT 234/586 190/599 46.9 % 1.26 [ 1.08, 1.47 ]
GEFAL 30/246 24/239 6.1 % 1.21 [ 0.73, 2.02 ]
IVAN 80/296 81/314 19.6 % 1.05 [ 0.80, 1.37 ]
LUCAS 33/214 51/218 12.6 % 0.66 [ 0.44, 0.98 ]
MANTA 18/154 15/163 3.6 % 1.27 [ 0.66, 2.43 ]
Subramanian 2010 2/20 0/8 0.2 % 2.14 [ 0.11, 40.30 ]
VIBERA 22/107 6/54 2.0 % 1.85 [ 0.80, 4.29 ]
Total (95% CI) 1844 1821 100.0 % 1.12 [ 1.00, 1.26 ]
Total events: 453 (Bevacizumab), 404 (Ranibizumab)
Heterogeneity: Chi2 = 11.78, df = 7 (P = 0.11); I2 =41%
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 3 Arterial thromboembolic event.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 3 Arterial thromboembolic event
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATT 29/586 28/599 51.1 % 1.06 [ 0.64, 1.76 ]
GEFAL 1/246 1/239 1.9 % 0.97 [ 0.06, 15.44 ]
IVAN 10/296 13/314 23.3 % 0.82 [ 0.36, 1.83 ]
LUCAS 3/214 10/218 18.3 % 0.31 [ 0.09, 1.10 ]
MANTA 5/154 3/163 5.4 % 1.76 [ 0.43, 7.26 ]
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 1603 1587 100.0 % 0.90 [ 0.62, 1.32 ]
Total events: 48 (Bevacizumab), 55 (Ranibizumab)
Heterogeneity: Chi2 = 4.07, df = 4 (P = 0.40); I2 =2%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 4 Gastrointestinal perforation.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 4 Gastrointestinal perforation
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 107 54 Not estimable
Total events: 0 (Bevacizumab), 0 (Ranibizumab)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 5 Infections.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 5 Infections
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATT 54/586 41/599 68.9 % 1.35 [ 0.91, 1.99 ]
GEFAL 4/246 2/239 3.4 % 1.94 [ 0.36, 10.51 ]
IVAN 12/296 9/314 14.8 % 1.41 [ 0.60, 3.31 ]
LUCAS 3/214 4/218 6.7 % 0.76 [ 0.17, 3.37 ]
MANTA 3/154 3/163 5.0 % 1.06 [ 0.22, 5.16 ]
VIBERA 3/107 0/54 1.1 % 3.56 [ 0.19, 67.79 ]
Total (95% CI) 1603 1587 100.0 % 1.35 [ 0.97, 1.87 ]
Total events: 79 (Bevacizumab), 59 (Ranibizumab)
Heterogeneity: Chi2 = 1.26, df = 5 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.073)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 6 Myocardial infarction.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 6 Myocardial infarction
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATT 7/586 9/599 40.1 % 0.80 [ 0.30, 2.12 ]
GEFAL 1/246 1/239 4.6 % 0.97 [ 0.06, 15.44 ]
IVAN 4/296 4/314 17.5 % 1.06 [ 0.27, 4.20 ]
LUCAS 0/214 6/218 29.0 % 0.08 [ 0.00, 1.38 ]
MANTA 3/154 2/163 8.8 % 1.59 [ 0.27, 9.37 ]
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 1603 1587 100.0 % 0.71 [ 0.37, 1.35 ]
Total events: 15 (Bevacizumab), 22 (Ranibizumab)
Heterogeneity: Chi2 = 3.48, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 7 Neutropenia.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 7 Neutropenia
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 107 54 Not estimable
Total events: 0 (Bevacizumab), 0 (Ranibizumab)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.8. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 8 Non-ocular haemorrhage.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 8 Non-ocular haemorrhage
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GEFAL 0/246 3/239 49.8 % 0.14 [ 0.01, 2.67 ]
IVAN 1/296 3/314 40.9 % 0.35 [ 0.04, 3.38 ]
VIBERA 1/107 0/54 9.3 % 1.53 [ 0.06, 36.89 ]
Total (95% CI) 649 607 100.0 % 0.36 [ 0.08, 1.50 ]
Total events: 2 (Bevacizumab), 6 (Ranibizumab)
Heterogeneity: Chi2 = 1.19, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 6.9. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 9 Stroke.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 9 Stroke
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATT 8/586 8/599 43.1 % 1.02 [ 0.39, 2.71 ]
GEFAL 0/246 0/239 Not estimable
IVAN 3/296 6/314 31.7 % 0.53 [ 0.13, 2.10 ]
LUCAS 2/214 3/218 16.2 % 0.68 [ 0.11, 4.02 ]
MANTA 1/154 1/163 5.3 % 1.06 [ 0.07, 16.77 ]
VIBERA 1/107 0/54 3.6 % 1.53 [ 0.06, 36.89 ]
Total (95% CI) 1603 1587 100.0 % 0.83 [ 0.42, 1.63 ]
Total events: 15 (Bevacizumab), 18 (Ranibizumab)
Heterogeneity: Chi2 = 0.80, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 6.11. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 11 Vascular events associated with anti-VEGF treatment.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 11 Vascular events associated with anti-VEGF treatment
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATT 62/586 45/599 63.8 % 1.41 [ 0.98, 2.03 ]
IVAN 17/296 26/314 36.2 % 0.69 [ 0.38, 1.25 ]
Subramanian 2010 0/20 0/8 Not estimable
Total (95% CI) 902 921 100.0 % 1.15 [ 0.85, 1.56 ]
Total events: 79 (Bevacizumab), 71 (Ranibizumab)
Heterogeneity: Chi2 = 3.99, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 6.12. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 12 Cardiac disorders MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 12 Cardiac disorders MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATT 62/586 47/599 62.0 % 1.35 [ 0.94, 1.94 ]
GEFAL 2/246 5/239 6.8 % 0.39 [ 0.08, 1.98 ]
IVAN 19/296 20/314 25.9 % 1.01 [ 0.55, 1.85 ]
VIBERA 7/107 3/54 5.3 % 1.18 [ 0.32, 4.37 ]
Total (95% CI) 1235 1206 100.0 % 1.19 [ 0.88, 1.59 ]
Total events: 90 (Bevacizumab), 75 (Ranibizumab)
Heterogeneity: Chi2 = 2.56, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 6.13. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 13 Gastrointestinal disorders MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 13 Gastrointestinal disorders MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATT 28/586 11/599 43.3 % 2.60 [ 1.31, 5.18 ]
GEFAL 3/246 5/239 20.2 % 0.58 [ 0.14, 2.41 ]
IVAN 9/296 3/314 11.6 % 3.18 [ 0.87, 11.64 ]
LUCAS 6/214 5/218 19.7 % 1.22 [ 0.38, 3.95 ]
MANTA 0/154 0/163 Not estimable
VIBERA 3/107 1/54 5.3 % 1.51 [ 0.16, 14.21 ]
Total (95% CI) 1603 1587 100.0 % 1.93 [ 1.20, 3.11 ]
Total events: 49 (Bevacizumab), 25 (Ranibizumab)
Heterogeneity: Chi2 = 4.65, df = 4 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.72 (P = 0.0066)
Test for subgroup differences: Not applicable
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Analysis 6.14. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 14 General disorders and administration site conditions MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 14 General disorders and administration site conditions MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GEFAL 4/246 0/239 3.4 % 8.74 [ 0.47, 161.55 ]
IVAN 16/296 15/314 96.6 % 1.13 [ 0.57, 2.25 ]
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 649 607 100.0 % 1.39 [ 0.73, 2.65 ]
Total events: 20 (Bevacizumab), 15 (Ranibizumab)
Heterogeneity: Chi2 = 1.87, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 6.15. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 15 Neoplasms benign, malignant, and unspecified MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 15 Neoplasms benign, malignant, and unspecified MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATT 22/586 27/599 52.4 % 0.83 [ 0.48, 1.45 ]
GEFAL 1/246 1/239 2.0 % 0.97 [ 0.06, 15.44 ]
IVAN 14/296 11/314 21.0 % 1.35 [ 0.62, 2.93 ]
LUCAS 10/214 8/218 15.6 % 1.27 [ 0.51, 3.16 ]
MANTA 1/154 2/163 3.8 % 0.53 [ 0.05, 5.78 ]
VIBERA 3/107 2/54 5.2 % 0.76 [ 0.13, 4.40 ]
Total (95% CI) 1603 1587 100.0 % 1.00 [ 0.68, 1.46 ]
Total events: 51 (Bevacizumab), 51 (Ranibizumab)
Heterogeneity: Chi2 = 1.64, df = 5 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 6.16. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 16 Nervous system disorders MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 16 Nervous system disorders MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATT 36/586 34/599 74.7 % 1.08 [ 0.69, 1.71 ]
GEFAL 3/246 0/239 1.1 % 6.80 [ 0.35, 130.98 ]
IVAN 8/296 9/314 19.4 % 0.94 [ 0.37, 2.41 ]
LUCAS 1/214 0/218 1.1 % 3.06 [ 0.13, 74.60 ]
MANTA 2/154 1/163 2.2 % 2.12 [ 0.19, 23.11 ]
VIBERA 1/107 0/54 1.5 % 1.53 [ 0.06, 36.89 ]
Total (95% CI) 1603 1587 100.0 % 1.17 [ 0.79, 1.73 ]
Total events: 51 (Bevacizumab), 44 (Ranibizumab)
Heterogeneity: Chi2 = 2.29, df = 5 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 6.17. Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses,
Outcome 17 Respiratory, thoracic, and mediastinal disorders MedDRA Class.
Review: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Comparison: 6 Bevacizumab versus ranibizumab, secondary analysis: fixed-effect analyses
Outcome: 17 Respiratory, thoracic, and mediastinal disorders MedDRA Class
Study or subgroup Bevacizumab Ranibizumab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GEFAL 4/246 4/239 34.3 % 0.97 [ 0.25, 3.84 ]
IVAN 7/296 8/314 65.7 % 0.93 [ 0.34, 2.53 ]
VIBERA 0/107 0/54 Not estimable
Total (95% CI) 649 607 100.0 % 0.94 [ 0.42, 2.12 ]
Total events: 11 (Bevacizumab), 12 (Ranibizumab)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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